Self-healing Poly(methyl methacrylate) Bone Cement Utilizing Embedded Microencapsulated 2-Octyl Cyanoacrylate Tissue Adhesive by Brochu, Alice
 i
v 
 
 
Self-healing Poly(methyl methacrylate) Bone Cement Utilizing Embedded 
Microencapsulated 2-Octyl Cyanoacrylate Tissue Adhesive 
 
by 
Alice Bradbury Welsh Brochu 
Department of Biomedical Engineering 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
William M. Reichert, Supervisor 
 
___________________________ 
Stephen Craig 
 
___________________________ 
Jan Genzer 
 
___________________________ 
Farshid Guilak 
 
___________________________ 
Bruce Klitzman 
 
Dissertation submitted in partial fulfillment of 
the requirements for the degree of Doctor 
of Philosophy in the Department of 
Biomedical Engineering in the Graduate School 
of Duke University 
 
2013 
 
  
 
 
ABSTRACT 
Self-healing Poly(methyl methacrylate) Bone Cement Utilizing Embedded 
Microencapsulated 2-Octyl Cyanoacrylate Tissue Adhesive 
 
by 
Alice Bradbury Welsh Brochu 
Department of Biomedical Engineering 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
William M. Reichert, Supervisor 
 
___________________________ 
Stephen Craig 
 
___________________________ 
Jan Genzer 
 
___________________________ 
Farshid Guilak 
 
___________________________ 
Bruce Klitzman 
 
An abstract of a dissertation submitted in partial 
fulfillment of the requirements for the degree 
of Doctor of Philosophy in the Department of 
Biomedical Engineering in the Graduate School of 
Duke University 
 
2013  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Alice Bradbury Welsh Brochu 
2013 
 
  
iv 
Abstract 
Extending the functional lifetime of acrylic poly(methyl methacrylate) (PMMA) 
bone cement may reduce the number of revision total joint replacement (TJR) surgeries 
performed each year.  We developed a system utilizing an encapsulated water-reactive, 
FDA-approved tissue adhesive, 2-octyl cyanoacrylate (OCA), as a healing agent to repair 
microcracks within a bone cement matrix.  The proposed research tested the following 
hypotheses: (1) reactive OCA can be successfully encapsulated and the resulting 
capsules thoroughly characterized; (2) the static mechanical properties of the PMMA 
composite can be improved or maintained through inclusion of an optimal wt% of OCA-
containing capsules; (3) PMMA containing encapsulated OCA has a prolonged lifetime 
when compared with a capsule-free PMMA control as measured by the number of 
cycles to failure; and (4) the addition of capsules to the PMMA does not significantly 
alter the biocompatibility of the material.  Based on the experiments reported herein, the 
primary conclusions of this dissertation are as follows: (1) functional OCA can be 
encapsulated within polyurethane spheres and successfully incorporated into PMMA 
bone cement; (2) lower wt% of capsules maintained the tensile, compressive, fracture 
toughness, and bending properties of the PMMA; (3) inclusion of 5 wt% of OCA-
containing capsules in the matrix increased the number of cycles to failure when 
compared to unfilled specimens and those filled with OCA-free capsules; and (4) MG63 
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human osteosarcoma cell proliferation and viability were unchanged following 
exposure to OCA-containing PMMA when compared with a capsule-free control.   
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1. Chapter 1: Background, significance, specific aims, 
and hypotheses  
Some of the text, figures, and modified versions of the tables included in Chapter 
1 were previously published in the February 2011 edition of the Journal of Biomedical 
Materials Research Part A.  The full citation for the article is: Brochu, A. B. W., Craig, S. 
L. and Reichert, W. M. (2011), Self-healing biomaterials. J. Biomed. Mater. Res., 96A: 
492–506. doi: 10.1002/jbm.a.32987.  John Wiley & Sons Ltd. does not require permission 
for authors to reuse their own articles, but an optional grant of license can be obtained 
and is included in Appendix B. 
 
1.1 Background and significance 
1.1.1 Total joint replacements 
1.1.1.1 Clinical need for and design of total joint replacements 
In the United States, more than 16 million individuals are affected by some form 
of arthritis, the most common types of which are osteoarthritis (OA) and rheumatoid 
arthritis[1].  OA is a degenerative condition characterized by joint pain and mild 
inflammation associated with the mechanical failure of articular cartilage[1, 2].  OA is the 
leading cause of disability and functional limitation in adults[3] and more than 59 million 
cases are expected by the year 2020[1].  Primary treatments for arthritis are 
acetaminophen and non-steroidal anti-inflammatory medications such as Tylenol and 
Advil; physical therapy is also recommended to reduce pain and improve range of 
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motion in the affected joint(s).  Injections of powerful steroids, such as cortisone, directly 
into the joint space are also used to temporarily reduce pain and inflammation[4].  
However, none of these treatment options repair the cartilage damage and merely serve 
to manage the symptoms. 
Total joint replacements (TJRs) have become the gold standard to manage the 
pain and cartilage loss associated with OA when the pain becomes unmanageable[5, 6].  
Numerous joint replacements are clinically-approved, including those for the hip, knee, 
shoulder, ankle, wrist, elbow, and finger[7].  Replacements generally involve (1) a 
metallic endoprosthesis inserted into the boney tissue, (2) polymeric ultra-high 
molecular weight polyethylene (UHMWPE) articulating surfaces, and (3) an acrylic 
poly(methyl methacrylate) (PMMA) cement to anchor the prosthesis within the native 
tissue[8].   
PMMA bone cement is a space-filling matrix that forms mechanical interlocks 
between the implant stem and the surrounding boney tissue[9, 10], serving to transfer 
loads from the prosthesis to the bone[11].  Bone cement consists of two components: (1) a 
low molecular weight PMMA powder containing a radiopacifier (e.g. barium sulfate) 
and an initiator (e.g. benzoyl peroxide) and (2) liquid methyl methacrylate (MMA) 
monomer.  Mixing the two components in situ initiates an exothermic polymerization to 
yield a workable dough, which is applied to the implant and cures into a solid mass 
after the implant is inserted[8, 9].   
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While not all joint replacements are cemented, data from 2010 reports that 92% of 
primary total knee and 12% of primary total hip replacements performed in the United 
States utilized bone cement[12-14].  There are projected to be 332,000 hip, 719,000 knee, 
40,000 total shoulder, 30,000 hemishoulder, and 5,000 elbow replacements per year by 
2013[12, 15, 16]; nearly all of shoulder, hemishoulder, and elbow TJRs performed to date are 
cemented[15].  These numbers do not take into account the number of revision procedures 
performed each year.  
By 2030, demand for primary hip replacement procedures is expected to increase 
by 174% in the United States[17, 18]; demand for primary knee replacement procedures is 
expected to be much higher, with a projected increase of 673% over the same time 
period[18].  These increases are primarily driven by the aging of the baby boomer 
generation and the obesity epidemic in the United States[19].  However, increased life 
expectancy and need for joint replacements at younger and more active ages will also 
play a significant role in the demand for these procedures[6, 20, 21].  Additionally, younger 
patients are considered at elevated risk for revision due to their higher activity levels in 
comparison with elderly patients.  Approximately 18% of total hip arthroplasties and 8% 
of total knee arthroplasties performed annually in the United States are revision 
procedures, indicating failure of the primary replacement[22].  Revision procedures are 
associated with elevated risks of complications including infection, dislocation, venous 
thromboembolism, and mortality; their complexity is reflected by higher hospital costs, 
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longer length of hospital stay, and longer operative time when compared with primary 
procedures[22].  Moreover, the average lifetime of a revised prosthesis is significantly 
lower than that of a primary implant[23, 24].  Cement usage is more common in revision 
procedures to further stabilize the TJR in the event of osteolysis, the active resorption of 
bone matrix by osteoclasts, resulting from the primary replacement.  As the prevalence 
of revisions increases[22], so will the number of cemented procedures. 
 
1.1.1.2 Sources of failure observed in total joint replacements 
Bone resorption, bone fracture, cement/bone separation, cement/prosthesis 
separation, microcrack formation in the cement, and the generation of wear debris from 
the articulating surfaces, metallic stem, and the bone cement itself serve to accelerate 
wear that often leads to loosening and subsequent failure of the implant[11, 18, 20, 25-30].  
Aseptic loosening of TJRs is a disabling condition that generally affects patients more 
than 10 years after surgery; this loosening can result from factors such as inadequate 
initial implant fixation[31, 32], mechanical loss of fixation over time[33, 34], or biological loss 
of fixation resulting from osteolysis[33, 35-38].  While loosening can be attributed to various 
mechanisms, all are interconnected and serve to perpetuate the process that ultimately 
results in TJR failure and necessitates subsequent revision procedures. 
Stress shielding results when the loads within a joint are redistributed following 
a TJR, ultimately decreasing the loads transmitted to the bone[35].  Shielding is due to the 
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mismatch in stiffness between the implant and the native bone[39].  Mechanical load 
stimulates new bone formation[39]; bone is resorbed as the physiological loads sustained 
by the bone decrease and new bone is not deposited, further exacerbating the issue of 
bone integrity around the implant[40].  While stress shielding contributes to implant 
loosening, it is rarely the isolated cause of failure but accelerates failure from other 
means[35]; even if shielding is not the primary cause of loosening, preservation of the 
native bone is extremely important to prolong the functional lifetime of the TRJ and 
improve the success of any subsequent revision procedure.  Patient physical health also 
contributes to the functional lifetime of the implant; conditions such as osteoporosis or 
obesity can further compromise the success of a TJR[40].  As the initial mechanical fixation 
of the implant depends partially on the local bone mass and degree of osteolysis[35], 
stress shielding and osteoporosis both influence local bone density and contribute to the 
stability of implant fixation.   
The biologic response to implant debris is complex and results from multiple 
factors; wear particles can be generated from all materials within the TJR including the 
bone cement, metallic stem, and polymeric load-bearing surfaces[33, 35, 39].  The core of the 
biological response that leads to osteolysis is activation of the receptor activator of 
nuclear factor-ĸB (RANK)/RANK ligand (RANKL) axis that enhances osteoclast 
recruitment and activity at the bone/implant interface, promoting osteolysis[36].  Studies 
with human macrophages have found that direct interactions between wear particles 
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and cells are sufficient to activate the osteoclastic signaling pathways that precede 
osteolysis[37].  Because wear particles are often resistant to enzymatic degradation, their 
continued presence in the joint space further exacerbates the cell response and 
continuously promotes osteolysis[35, 36, 41].   Macrophages, fibroblasts and osteoblasts 
release pro-inflammatory cytokines that directly and indirectly stimulate osteoclast 
development[35, 37].  Additionally, greater concentrations of wear particles have been 
associated with more aggressive osteolysis and subsequent aseptic loosening[42]. 
Implant loosening is the primary cause of TRJ failure, but other factors also 
influence TJR failure.  Infections incurred during the surgical procedure occur in 0.3-2% 
of primary arthroplasties[43-45]; these infections result in complications such as 
discharging sinuses and scar tissue formation that produce debilitating patient pain[44] in 
addition to facilitating implant loosening.  Chronic infection also triggers the foreign 
body response that results in encapsulation of the implant.  Osteolysis brought on by 
infection also contributes to TJR failure but bone loss specifically from infection cannot 
be separated from that resulting from other mechanisms[44].  Several broad-spectrum 
antibiotics, including gentamicin sulphate, vancomycin chloride, and tobramycin, have 
been incorporated into bone cement to fight infection[46]; the costs associated with these 
additions is estimated to be more than $250 million/year in the United States alone[43].  
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1.1.1.3 Strategies to improve the functional lifetime of total joint replacements 
Straightforward attempts to improve implant stability have focused on 
improving the fixation between the implant and the native boney tissue.  The simplest 
solution is the use of PMMA bone cement to anchor the stem of the implant and transfer 
loads between it and the native tissue.  As bone cement is considerably weaker than 
bone[11] and comes with its own set of challenges, researchers have proposed composite 
designs to improve the mechanical properties of the material; dispersed particulates and 
fibers have been investigated to increase the toughness, impact strength, and wear 
resistance of the PMMA by absorbing a greater fraction of the load, inhibiting pathways 
for crack propagation, and resisting void formation.  However, in spite of a long history 
of development in load-bearing applications, very few composite devices have 
progressed to widespread clinical use[47]. 
Glass polyalkenoate cements, bioglass, various glass-ceramic compositions, 
antibiotic-containing cements[46], and calcium phosphate cements[48] have been 
investigated to minimize failure and promote integration at the bone/PMMA interface.  
Other techniques to improve TJR materials include modifying the implant stem with 
coatings of hydroxyapatite[39, 49-51] or silicate glasses[39] to stimulate bone adhesion; such 
coatings have also been used in combination with rough and/or sintered stem surfaces 
to facilitate interlocking with the tissue and promote bone ingrowth in the absence of 
bone cement[35, 40, 50-52].   
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In addition to improving implant-bone integration, therapeutic interventions 
have been investigated to target cells that contribute to osteolysis and subsequent 
aseptic loosening, such as osteoclast precursor cells and non-osteoclast precursor cells 
that are stimulated by debris to differentiate into osteoclasts.  Direct inhibition of 
osteoclast differentiation has been investigated using molecules that bind to RANKL to 
inhibit bone loss, resulting in reduced osteolysis[37, 53, 54].  Strategies to locally inhibit 
cytokine production could also be used to mediate joint inflammation[36].  For example, 
strategies to reduce tumor necrosis factor (TNF) or block its receptors on osteoclasts 
have been investigated as treatments to prevent aseptic loosening[37, 55] by inhibiting the 
potent osteoclastogenic action of TNF-α[56].  Additionally, drugs such as 
bisphosphonates that are currently used to treat bone diseases such as osteoporosis have 
also been proposed to inhibit osteoclast function and induce osteoclast apoptosis[37, 57, 58].   
Other strategies focus on the improvement of the properties of the implant 
materials themselves to reduce the generation of wear debris and resulting osteolysis 
rather than attempting to mediate it after the fact.  Ceramics[33, 59] and highly polished 
metal heads[39] have been introduced in an attempt to minimize the generation of wear 
debris from UHMWPE surfaces in joint replacements.  There is also significant interest 
in metal-metal and ceramic-ceramic TJRs[33, 39, 59].  To increase the wear resistance of 
titanium alloys commonly used in TJRs, nitriding processes such as plasma and laser 
nitriding as well as ion implantation have been used to enhance the tribological 
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properties of titanium and its alloys[60].  Variations in the alloy compositions have also 
been investigated to improve wear and corrosion resistance, decrease the modulus to 
approach that of native bone, and improve biocompatibility[39, 60-62]. 
 
1.1.2 Self-healing materials 
1.1.2.1 What are self-healing materials? 
Self-healing materials (SHM) are a rapidly emerging class of composites with 
applications primarily designed for use in the civil, mechanical, electrical, and aerospace 
industries.  These materials hold the potential for significantly extending functional 
lifetimes by preventing and repairing failures caused by accumulated microdamage.  To 
date, the majority of research conducted on self-healing bulk materials has employed 
composites, adhesives, and cements intended for traditional engineering applications[63-
70].  One of the most broadly reported self-healing schemes is that pioneered by White 
and Sottos et al. in which a polymer matrix is co-embedded with a catalyst and 
microcapsules containing a reactive healing agent (Figure 1.1).  Once encountered by a 
propagating microcrack, the microcapsule shell ruptures, releasing the healing agent 
into the crack plane and exposing it to the catalyst embedded in the matrix.  In situ 
curing of the healing agent ensues, halting crack propagation[47, 63-65, 71-73]. 
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Figure 1.1: Self-healing material scheme[47].  Adopted from[65]. 
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Although this field has been steadily growing over the past 10 years, very little 
discussion of extension into biomaterials has taken place and none of the existing 
systems employ materials acceptable for in vivo applications.   Table 1.1 summarizes 
some of the many systems proposed for SHM using the matrix repolymerization 
material design approach[47].   
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Table 1.1: Summary of healing agents, catalysts, and matrix materials studied for 
applications in SHM based on the matrix repolymerization scheme 
Matrix material Healing agent Catalyst References 
Vinyl ester HOPDMS and PDES (phase 
separated in matrix) 
DBTL in PUR 
microcapsules 
[71, 74] 
EPON 828 cured 
with DETA 
DCPD in UF capsules Grubbs’ catalyst in 
paraffin wax 
microspheres 
[75, 76] 
PMMA DCPD in UF capsules Grubbs’ catalyst [77] 
EPON 828 cured 
with DETA 
EPON 862 or 828 diluted with 
cholorobenzene, 
phenylacetate, ethyl 
phenylacetate  in UF capsules 
None [66] 
EPON 828 cured 
with DETA 
DCPD in UF capsules Grubbs’ catalyst [63-65, 78, 79] 
YD-115 cured 
with KH-816 
DCPD in UF capsules Grubbs’ catalyst [78, 79] 
YD-115 cured 
with KH-816 
ENB in UF capsules Grubbs’ catalyst [78, 79] 
Silver particle ink 
lines on a PUR 
substrate 
Silver ink in acrylic capsules Encapsulated hexyl 
acetate that, when 
released, dissolves 
acrylic capsule to 
release silver ink 
[80] 
EPON 828 cured 
with DETA 
EPON 815C in UF capsules EPIKURE 3274 
polyamine 
[81] 
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1.1.2.2 Challenges for extension into biomaterials 
Numerous implants fail following the accumulation of damage and are potential 
candidates for the introduction of self-healing to biomaterials.  However, as there are 
stringent requirements for materials used in clinical applications, any SHM proposed for 
a biomedical application would need to be assessed from mechanical, biocompatibility, 
and self-healing perspectives.  There are several concerns associated with SHM based on 
the repolymerization scheme depicted in Figure 1.1; these concerns along with some 
specific to biomaterials are summarized in Table 1.2[47].   
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Table 1.2: Concerns associated with SHM and their extension to biomaterials 
General Concerns References 
Healing agent/catalyst consumption [63, 69] 
Healing agent stability in microcapsules [64-66] 
Microcapsule shell process survivability [65, 66] 
Effective release of healing agent from capsule [65, 72] 
Capsule/matrix interfacial bonding [65, 66, 72] 
Healing agent viscosity and volatility [66, 78, 79] 
Uneven healing agent/catalyst distribution or ratios within matrix [64, 69, 75, 82, 83] 
Concerns Specific to Biomaterials  
Healing may require times not feasible with cyclically-loaded implants [64, 71] 
Complex and variable loading patterns may limit healing opportunities [47] 
Functional lifetime of encapsulated healing agent [47] 
Toxicity of the healing agent/catalyst system [47] 
Surgeon ease-of-use dictates adoption of material [47] 
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Due to its long history of use and significant potential for increased future use, 
lack of post-polymerization modifications, and need for improvement, the development 
of a self-healing PMMA bone cement is a very attractive option for the first self-healing 
biomaterial designed with the aforementioned embedded capsule and catalyst 
approach[47, 84].  The projections and statistics included in section 1.1.1.1 indicate there are 
a significant number of potential beneficiaries of any steps taken to improve existing 
bone cement and extend implant functional lifetime.   
 
1.1.2.3 Strategies commonly used to assess self-healing materials 
Tapered and width-tapered double cantilever beam (TDCB and WTDCB, 
respectively) testing protocols are currently the literature standards used to assess the 
healing efficiency of existing systems in response to controlled crack propagation.  
TDCB testing determines mode I fracture toughness (K) and the geometry is designed 
such that the profile of the taper provides a constant value of K over a desired range of 
crack lengths[85].  The WTDCB geometry has been used to investigate the healing of 
delamination and thin film failures and is similarly designed so that the energy release 
rate remains constant over a desired range of crack lengths[64].  Fracture specimens of 
each type are tested under displacement control, applying a vertical load to induce crack 
propagation within a grooved centerline region of the specimen[64, 85].  
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Typically, the healing efficiency of a SHM is determined by testing the “virgin” 
specimen until a crack propagates through the center of the material; the separate pieces 
are reapposed to allow the healing agent to react and bond the surfaces together and the 
“healed” specimen is then tested again.  The most desirable feature of TDCB and 
WTDCB specimens is that the geometries exhibit a linear relationship between critical 
load (PC) and fracture toughness independent of crack length, allowing the healing 
efficiency (ƞ) to be expressed as show in Equation 1[65, 85]: 
   
       
       
   
        
        
                                                                     
 
While this equation holds for both geometries, the two methods have several 
distinctions.  For example, each TDCB sample must be molded separately whereas 
numerous WTDCB samples may be machined from one larger sheet of material.  TDCB 
testing has been used to assess the healing efficiency of numerous systems[65, 74-76]; 
however, the WTDCB geometry is limited to describe delamination fracture toughness[64] 
and self-healing for thin adhesive films[86]. 
Most studies utilizing these geometries to investigate healing efficiency have 
induced crack propagation through a single, continuously applied load[65, 74-76].  However, 
given that SHM are designed to prevent accumulated damage, their healing efficiency 
under cyclic loading has also been investigated[86-89].  Brown et al. reported that when 
healing agent was released into the crack plane of a cyclically-loaded TDCB specimen it 
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polymerized to form a polymer wedge, generating a crack tip shielding mechanism[87, 88].  
This shielding wedge resulted in temporary crack arrest and extended the fatigue 
lifetime by 20 times.  Hydrodynamic pressure crack-tip shielding due to viscous flow 
was also found to retard crack growth[87], indicating that the initiation of healing agent 
polymerization could act to slow crack growth before full polymerization and 
subsequent polymer wedge formation.  The forces required to squeeze a viscous fluid 
from the crack plane during unloading provided crack-tip shielding.   
While TDCB and WTDCB tests currently provide valuable information about the 
healing efficiency of some systems, these methods introduce very large defects that are 
not representative of damage likely to be sustained in vivo.  A more clinically-relevant 
and informative procedure would involve assessing the healing capabilities of a self-
healing bone cement system under in vivo conditions to repair microdamage.   
 
1.1.3 Characterization of PMMA bone cement 
1.1.3.1 Determination of various mechanical properties  
Several protocols for PMMA testing have been developed over its long history of 
usage in biomaterials.  The total loading is a mixture of compressive, bending, tensile, 
shear, and torsional forces[90] and as such, procedures to determine the mechanical 
properties involve the application of various static or dynamic stresses. 
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1.1.3.1.1 Compression testing 
A material’s ultimate compressive strength (UCS) is the maximum stress it can 
withstand before failure under compression.  ASTM F451 describes compressive testing 
protocols; it requires the time between the mixing of the cement and the measurement of 
the compressive strength be no more than 24 ± 2 h, with tests performed at 23 ± 2 ºC and 
50 ± 10% relative humidity.  Deformation is applied at a cross-head speed of 20-25.4 
mm/min.  Failure load is determined as the load at the 2.0% offset, upper yield point, or 
fracture, depending on which occurs first.  At least five samples must be tested and the 
minimum acceptable compressive strength is 70 MPa[91]. 
1.1.3.1.2 Tensile testing 
The ultimate tensile strength (UTS) is the maximum stress a material can 
withstand before failure under tension.  ASTM D638 describes a static, uniaxial tensile 
test applicable for polymeric materials and requires at least 5 samples be tested at 23 ± 2 
ºC on any universal testing machine.  Prior to testing, the specimens must be measured 
within 5 mm of each end of the gage length to confirm cross-sectional area.  The 
specimen is placed between the grips of the testing machine and tightened evenly and 
firmly to prevent slippage during the test but without crushing the sample[92].  An 
extension rate of 5 ± 1 mm/min is used to deform the samples.  Though there is no 
minimum acceptable UTS dictated by standards, commercial bone cements have 
literature-reported values ranging from 25-70 MPa[21, 90, 93]. 
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1.1.3.1.3 Bending testing 
Bending is a combination of tensile and compressive loading and is therefore a 
more realistic test of the bone cement’s properties in vivo.  ISO 5833 describes a four-
point bending protocol to determine the bending strength (B) and modulus (E) of 
materials. The bending modulus is a ratio of stress to strain of the material within the 
elastic range characterizing the relative stiffness of the material[90].  ISO 5833 requires the 
time between the mixing of the cement and the measurement of the bending strength 
and modulus be no more than 24 ± 2 h with tests performed at 23 ± 1 ºC.  The inner 
loading points are separated by 20 mm and the outer loading points separated by 60 
mm.  A cross-head speed of 5 ± 1 mm/min is applied on the inner loading points and the 
deflection of the specimen measured as a function of the applied force; the testing is 
continued through specimen failure.  At least five samples must be tested and the 
minimum acceptable B and E of bone cement are 50 and 1800 MPa, respectively[94].   
1.1.3.1.4 Fracture toughness testing 
Fracture toughness is a measure of a material’s ability to resist unstable crack 
propagation; crack initiation and propagation rates contribute to this property.  Fracture 
toughness can be determined using a variety of notched specimen types, such as TDCB 
samples; these samples are tested 24 ± 2 h after fabrication at 23 ± 1 ºC under applied 
loads at various speeds.  The variation of the testing geometries and protocols used 
results in literature-reported values ranging from 0.88-2.58 MPa m1/2 [11, 95-98].     
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1.1.3.1.5 Fatigue testing 
Long-term strength under alternating loads determines the durability of bone 
cement; therefore, fatigue testing provides information about the reliability of the 
cement for in vivo applications[99, 100].  If applied a sufficient number of times, the stress 
required to produce fatigue failure is generally much lower than that required to 
fracture the material under a single application[101].  A variety of procedures can be used 
to characterize the fatigue behavior of PMMA, including: four-point bending testing 
following ISO 5833, pure tensile testing following ISO 527, and uniaxial compression-
tensile testing following ASTM F2118[90].  In each of these tests, sinusoidal cyclic loading 
is applied until specimen failure or runout at a predetermined number of cycles.  
However, due to the simplicity of the four-point bending testing configuration described 
in ISO 5833 and the complexity of the preparation of samples following ASTM F2118, 
four-point bending testing is the preferred method of fatigue testing[90, 99, 100].  A protocol 
and set-up identical to that used for bending testing is followed.  
 Five specimens must be tested to bending failure to determine the quasi-static 
strength of the samples and to establish the average strength as a reference value.  
During fatigue studies, specimens should be submitted to cyclic loading at a 
physiologically-relevant frequency (i.e. 1-5 Hz[8, 102-105]) that is continued until failure 
occurs.  Various load levels ranging from 35-90% of the reference value are selected as 
testing conditions and at least five samples are tested at each load level[94, 106].  Under 
load control, the upper limit of the applied cycling force is kept constant; the standard 
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does not specify a value for R = σmin/σmax, although values ranging from -1 to 1 have been 
used previously, depending on the test configuration[100, 105].  Tests should be performed 
under load control as physiological strain is almost exclusively dictated by force[99, 100].  
Displacement-controlled protocols are easier to perform[99, 105], but are less accurate than 
load-controlled procedures and overestimate material lifetimes, subsequently under-
rating the risk of failure[90, 99, 106].   
1.1.3.1.6 Other testing procedures 
Shear strength plays a role in the debonding sometimes seen at the implant stem-
bone cement interface and is assessed following ASTM D732; impact strength is assessed 
using ISO 179, ISO 180, and DIN 53435.  Because PMMA is a viscoelastic material, creep 
and stress relaxation may contribute to implant loosening[11, 90]; creep measurements are 
made using ASTM D2990.   
1.1.3.1.7 Other considerations 
The properties of bone cement vary widely depending on water absorption, 
preparation variations and subsequent porosity differences (hand versus vacuum 
mixing), sterilization protocols, composition variations and additives, temperature, 
strain rate, etc.[11].  For example, hand-mixing results in a more porous matrix, generally 
decreasing the overall strength[8, 11, 90, 106].  Variability in the preparation and testing 
protocols complicate cross-comparison of results[105]; however, for the purposes of this 
research, commercial and self-healing matrices will be manufactured under identical 
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conditions and therefore similar levels of variability are expected across the 
experiments. 
1.1.3.1.8 Properties of PMMA bone cement 
Commercial formulations of PMMA bone cement have widely varying 
properties based on the aforementioned factors; the ranges of values for several 
properties are summarized in Table 1.3: 
 23 
Table 1.3: Properties of PMMA bone cement 
Property Reported value(s) References 
Ultimate tensile strength 25-70 MPa [11, 21, 90, 93, 107] 
Ultimate compression strength 66-103 MPa [11, 108] 
Bending strength  62-77 MPa [90] 
Young’s modulus 1.36-3.07 GPa [11, 107, 109, 110] 
Fracture toughness 0.88-2.58 MPa m1/2 [11, 95-97, 111] 
Density  1.08-1.19 g/cm3 [11] 
Strain to failure 0.0086-0.01 [21] 
Poisson’s ratio 0.3-0.4 [112] 
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1.1.3.2 In vitro assessments of PMMA toxicity 
Due to its extensive usage in biomaterials, PMMA has been thoroughly 
investigated for adverse biological effects.  Primary concerns associated with PMMA-
based bone cements include localized cell death due to the exothermic reaction of the 
MMA and leaching of residual monomer from the matrix[113].  An estimated 3-5% of the 
MMA remains 15 minutes post-polymerization and is reduced to about 1-2% over time 
as the residues are eliminated through the bloodstream[114, 115].  N,N-dimethyl-p-toluidine, 
which is present in small amounts (≤ 2% of the liquid component)[116] and initiates 
polymerization when it reacts with benzoyl peroxide, is very toxic at low concentrations 
and is able to inhibit protein synthesis and cause chromosomal mutations[114]. 
MG63 human osteosarcoma cells have been used in many biocompatibility 
studies [113, 114, 117-120] because they share numerous features with normal human 
osteoblasts including secretion of insulin-like growth factor, binding proteins, matrix 
metalloproteinases, and osteocalcin.  Similar to undifferentiated osteoblasts, MG63 cells 
also synthesize collagen types I and III and have a low basal expression of alkaline 
phosphatase that is increased in response to 1,25-dihydroxyvitamin D3[117, 121].  
Furthermore, because they are transformed, MG63 cells are readily obtained in large 
numbers and are unlikely to show growth-related changes in antigen expression with 
increasing passages[118].  Other cell types, including fibroblast L-929 cells[117] and TE85 
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human osteosarcoma cells[121, 122], have previously been used to assess bone cement 
cytotoxicity, but MG63 cells more closely reproduce the qualities of human osteoblasts. 
Numerous assays can be used to determine the viability of cells.  The 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide[113, 117, 122-126] (MTT) assay, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay[122], neutral red assay[122], methylene assay[122], and calcein-
acetoxymethylester (calcein-AM) studies[127] have all been used to investigate cell 
viability.  These assays work in various ways but cell metabolic activity is generally 
detected through a response such as a color change or emergence of fluorescence.   
Bone proliferation is commonly used as a marker for biocompatibility; 
techniques such as 5-bromo- 2’-deoxyuridine (BrdU)[124], 5-ethynyl-2´-deoxyuridine 
(EdU)[128], and propidium iodide (PI) staining[113, 114, 129] have been used to determine if 
cement leachables interfered with the progression of cells through the cell cycle.  BrdU is 
a halogenated analogue of thymidine and is incorporated into cells that are actively 
synthesizing DNA during the period of BrdU exposure[114, 124, 130].  A fluorescein 
isothiocyanate (FITC)-labeled monoclonal antibody against BrdU can be used as a probe 
for BrdU incorporated into DNA.  EdU is a nucleoside analog containing an alkyne that 
reacts with an azide in a copper-catalyzed reaction to form a covalent bond.  These 
proliferation assays are reported to be more accurate and consistent than BrdU assays, 
without requiring DNA denaturation or harsh treatments[128].  PI binds by intercalation 
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to double-stranded DNA and RNA and when used in combination with RNase 
digestion, it serves as a probe for measuring cellular DNA content[114]; during the G1 
phase of cell proliferation, the DNA in a diploid cell is 2n and, following the successful 
replication of DNA during the S phase, cells in the G2 phase are 4n, resulting in double 
the fluorescence intensity detected by flow cytometry. 
 
1.1.3.3 Failure of PMMA bone cement 
Bone cement is a brittle material that is weak in tension and strong in 
compression.  The material has a low fracture energy through which cracks can 
propagate at stresses below the UTS[93]; however, it is susceptible to crack initiation and 
subsequent propagation resulting from the cyclic loading it experiences in vivo.  Crack 
initiation is generally associated with regions of high stress intensity, such as inclusions, 
voids, and other microdefects.  When the stress concentration at the crack initiation site 
exceeds the critical load Pc, propagation is initiated.  The formation of microcracks 
causes debonding at the cement/bone and cement/implant interfaces as well as the 
generation of PMMA wear debris that contributes to chronic inflammation and 
osteolysis. 
During cyclic loading, a material’s resistances to crack initiation and propagation 
are strong determinants of fatigue strength and lifetime.  It has been reported that in 
bone cement, resistance to unstable crack propagation is a more important characteristic 
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than resistance to crack formation[95] and in vivo, crack propagation behavior dominates 
over crack initiation behavior[30].  Crack growth rates previously observed during fatigue 
testing of PMMA range from 10-2 to 1 µm/cycle[30, 131].  Various groups have found that 
crack propagation rates are reduced in bone cement containing various fillers including 
radiopacifiers and carbon fibers[30, 131].  Prior research has demonstrated that propagation 
is slowed as a crack propagates from a brittle to ductile material[132].  Slower crack 
growth rates in studies of bone cements containing additives are attributed, at least in 
part, to the longer crack path required for propagation as well as the number of cycles 
required to transverse the distance of the additive.  An decrease in the rate of crack 
propagation results increased fatigue life[30].  
Intrinsic factors of the bone cement as well as its preparation techniques dictate 
the fatigue properties of the cured material[105].  Properties such as the composition of the 
bone cement, type of radiopacifying agent, and polymer molecular weight are intrinsic 
to the brand of bone cement and contribute to the fatigue properties of the material.  
Storage temperature, specimen fabrication and curing conditions, and mixing methods 
are also highly variable and dictate the fatigue properties of the resulting bone 
cement[105].  Some of these preparation techniques may not be appropriate or feasible for 
bone cement used clinically; for example, perfectly smooth samples are not 
representative of the bone cement seen at the bone and implant interfaces in vivo.   
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While microcrack formation contributes to implant loosening, PMMA is a 
viscoelastic material: creep deformation and stress relaxation may also affect the 
material and contribute to TJR loosening[11, 90].  Previous studies have found that bone 
cement subjected to 1% compressive strain showed stress relaxation by 24% within 8 h[11, 
133].   Creep deformation of bone cement in response to an applied stress of 10 MPa was 
also investigated; within the first 24 h, the creep strain varied between 55-70%[133].  
Deformation of the cement mantle facilitates debonding at the cement/bone and 
cement/stem interfaces to contribute to loosening. 
In addition to the loosening caused by microcrack formation within the bone 
cement, the generation of these cracks also releases PMMA wear debris.  Wear particles 
represent loss to the original implant material and their presence is problematic as it 
facilitates wear particle-induced osteolysis and contributes to third body wear 
mechanisms within the TRJ[35].  Cement mantle defects have also been shown to act as 
preferential access pathways for wear debris, enabling the debris to infiltrate the 
articulating space to further accelerate UHMWPE wear; this debris responsible for the 
formation of granulomatous tissue that contributes to implant loosening, as discussed 
previously[134]. 
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1.1.3.4 Biomimetic assessments of PMMA bone cement 
1.1.3.4.1 Ex vivo fatigue testing 
In addition to PMMA fatigue analyses utilizing simple specimen geometries and 
loading patterns, a variety of testing set-ups and modified protocols have been proposed 
to examine the behavior of bone cement in contact with a cyclically-loaded metallic 
stem[34, 38, 135-140].  These procedures allow for analysis of failure at the cement/stem and 
cement/bone interfaces, which serve as initiation sites for failure in vivo.  Reported 
systems vary drastically, from tensile loading of metal rods in contact with stationary 
bone cement[38] to complex devices that simulate the damage that occurs during gait and 
stair climbing[135, 140].   
Several investigators have examined simplified systems to mimic the cement 
interfaces in TRJs by applying a load to a metallic rod encased in bone cement[38, 136, 137].  
Raab et al. used a cylindrical shear specimen to investigate fracture formation at or near 
the cement/metal interface[38]; the metal was inserted into a mass of bone cement that 
cured around it.  The interfaces demonstrated fatigue properties that were far inferior to 
the fatigue properties of bulk bone cement, particularly following 30-60 d storage in 
physiological saline at 37 ºC[38]. 
Other groups employed strategies that are combinations of more complex 
loading and specimen geometry.  For example, Jeffers et al. utilized a simple modified 
implanted femoral geometry surrounded by bone cement and polyurethane foam to 
mimic the native bone tissue to investigate creep and cracking of the bone cement[34]; this 
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model enabled real-time observation of crack formation in the cement mantle.  In their 
system, a load horse applied joint reaction and abductor forces while a sinusoidal 
compressive force was applied to the head of the horse to mimic gait.  The metallic 
stems were either bonded to the bone cement or fabricated such that the stems were in 
contact with the bone cement but not bonded with it.  Catastrophic cement mantle 
fracture occurred in all unbonded samples at the distal end of the stem; however, dye 
penetrant analyses revealed only microcracks with the use of a grit-blasted stem bonded 
to the bone cement and no catastrophic damage was observed[34].  
Race et al. examined crack formation resulting from the cement/stem interface, 
cement/bone interface, and voids utilizing a custom-built stair climbing fixture in which 
cadaveric femora implanted with commercial hip stems were tested.  The system was 
designed such that the load and a moment were applied via a cup cemented to the 
upper part of the fixture to mimic the femoral head and abductor muscle movements in 
vivo[135].  For the first 150,000 cycles, the load varied from 10-80% of the peak load to 
mimic normal gait and for the next 150,000 cycles, the load varied from 10-100% of the 
peak load to mimic climbing stairs.  This study also recorded stem/cortex micromotion 
using steel reference spheres monitored by linear variable displacement transducers.  
They found that significantly more cracks were associated with the cement/bone 
interface than with the cement/stem interface and voids[135]. 
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Given the number of factors that could be varied in these tests, comparison 
across such studies is difficult.  The loading patterns, specimen geometry, implant 
surface preparation, conditioning time, mixing time and rate, cement type, testing 
conditions, pressure used during joining, and testing rates all contribute to the fatigue 
lifetime of the bulk PMMA and of its interfaces.  The general consensus from these ex 
vivo studies is that failure at the cement interfaces dictates the overall success of the 
implant and that appropriate ex vivo testing is crucial to anticipate in vivo results.   
1.1.3.4.2 In vivo animal models 
Several animal studies have examined the in vivo responses to bone cement; these 
include studies investigating tissue response[141], the effects of wear debris on the 
immune response and subsequent osteolysis[56, 142], and load-bearing properties of new 
formulations to be used in bone defect repair[143, 144]. 
Allen et al. examined the tissue response to the in situ polymerization of a two-
solution bone cement using a non-load bearing sheep model[141].  For their studies, an 11 
mm diameter hole was drilled into the trochlear groove of the femur and the bone 
cement was injected into the void.  A steel rod was inserted into the space to simulate 
the presence of a metallic stem.  The tissue response following 12 weeks was assessed by 
quantifying histomorphometric parameters such as bone volume; the two-solution and 
commercial bone cements produced similar tissue responses, but this model did not 
consider the effects of loading on the material and on the body’s response. 
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Other animal studies have investigated the immune response to TJR wear debris; 
these models attempted to investigate the in vivo response to wear debris without a load-
bearing implant.  Merkel et al. used a transgenic mouse model to examine the effects of 
TNF-α on osteolysis. Two types of transgenic mice were used: one in which the p55 TNF 
receptor gene has been deleted and one in which both the p55 and p75 TNF receptor 
genes had been deleted.  PMMA bone cement particles were placed under the external 
calvarial periosteum in direct contact with the sagittal aspects of both temporal bones for 
7 d.  Histological sections of the bones from wild type mice revealed the presence of a 
fibrous membrane with mononuclear cells containing phagocytosed PMMA particles.  
Additionally, this membrane contained numerous osteoclasts that resorbed the width of 
the calvarial bone in just 1 week.  An inflammatory membrane was not generated in 
either transgenic mouse model, indicating that targeting TNF and/or its p55 receptor 
may reduce wear debris-induced osteolysis[56]. 
A load-bearing rabbit tibia model has been used to investigate repair of 
segmental bone defects[143, 144].  Okada et al. inserted commercial PMMA and bioactive 
bone cements into 15 mm defects in rabbit tibia; in this model, the biomaterial was 
cyclically-loaded throughout the course of the study.  Animals were sacrificed 12 and 25 
weeks post-implantation and sections of the native tibia removed for tensile testing.  The 
tensile strength of the bone proximal to a defect repaired with a bioactive bone cement 
was higher than that of bone near a defect repaired with PMMA bone cement.  A similar 
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study was performed by Hautamaki et al. in which a porous fiber-reinforced bone 
cement was implanted and subsequent bone ingrowth over 8-20 weeks was 
quantified[144].  These studies utilized load-bearing models, but the in vivo forces 
experienced by rabbits and humans make it difficult to draw comparisons.  
While the in vivo cytotoxicity of PMMA has been thoroughly documented over 
its long history of use in cemented TJRs, characterizing the biomaterial response in an 
animal model is challenging but must be completed before new materials can progress 
to human testing.  In the case of responsive materials (such as SHM), the response in vivo 
could depend on changes in the material following loading and static implantation may 
not provide the necessary and relevant information.  Furthermore, to glean meaningful 
information from load-bearing orthopedic implant studies, large animals would more 
closely mimic the forces seen by TJRs in humans and therefore more accurately describe 
the in vivo material response to cyclic loading.   
 
1.2 Specific aims and hypotheses 
To assess the practicality of a self-healing PMMA biomaterial concept, we will 
examine the potential for encapsulating a biocompatible, FDA-approved water-reactive 
tissue adhesive, 2-octyl cyanoacrylate (OCA), commonly used as a substitute for sutures 
in surgeries[145].  By selecting a water-reactive monomer, the material design (Figure 1.1) 
is simplified because a matrix-embedded catalyst is no longer required.  Water present 
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in vivo will polymerize OCA released from ruptured microcapsules.  In general, work 
will focus on successfully encapsulating OCA, characterizing microcapsule properties, 
investigating the effects of the capsules on the bulk PMMA mechanical properties, 
assessing the healing efficiency of the incorporated system, and examining the response 
of cells to the capsule-embedded PMMA formulation.  The specific aims and hypotheses 
of this dissertation are as follows: 
 
Specific Aim 1: Encapsulate 2-octyl cyanoacrylate and thoroughly characterize the 
physical and mechanical properties of the capsules.  Interfacial polymerization of 
toluene-2,4-diisocyanate (TDI) and 1,4-butanediol (1,4-BD) will be used to encapsulate 
OCA within polyurethane (PUR) shells.  Various properties of the resulting capsules 
will be investigated, including their morphology, size distribution, shell thickness, 
thermal degradation behavior, individual compressive strength, contents, and adhesive 
functionality of the encapsulated agent.  Once the capsules have been fully 
characterized, preliminary PMMA incorporation studies will determine capsule process 
survivability and their potential to be used in a self-healing bone cement application. 
Hypothesis 1: An optimized interfacial polymerization procedure using TDI and 1,4-BD 
will produce robust PUR capsules containing OCA tissue adhesive retaining its 
reactivity.  
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Specific Aim 2: Characterize the static mechanical properties of a microcapsule-
embedded PMMA bone cement when compared with an unmodified commercial 
formulation.  Clinically-approved bone cements must undergo extensive testing to 
characterize their mechanical properties.  Although this project aims to develop a self-
healing bone cement, any new material proposed must also meet the standards set for 
commercial formulations.  The effects of the inclusion of capsules on the bone cement 
will be investigated following various ASTM protocols.  The capsule content will be 
incrementally increased so an accurate assessment of matrix strength as a function of 
capsule content can be determined.   
Hypothesis 2: The inclusion of an optimal weight content of capsules will either (1) 
maintain static mechanical properties within acceptable limits or (2) increase the 
strengths to values greater than those seen with commercial bone cement 
formulations, particularly at low capsule wt%. 
 
Specific Aim 3: Assess the bending properties and fatigue lifetime extension of the 
capsule-containing formulation when compared with the commercial material via load-
controlled cyclic testing. To obtain reference values and optimal capsule content for 
fatigue specimens, the bending strength as a function of capsule content will be 
measured.  The effects of microcapsules on bulk matrix properties only represent one 
facet of the composite testing - the healing ability of the matrix must also be 
 36 
characterized.  Cyclic loading will be applied to commercial and capsule-embedded 
specimens using the 4-point bending configuration described in ISO 5833 to determine if 
fatigue lifetime is increased through the incorporation of encapsulated OCA.  The 
susceptibility of capsules to moisture intrusion will also be analyzed to determine the 
potential duration of the functional lifetime of the material. 
Hypothesis 3: The inclusion of an optimal weight content of capsules will either (1) 
maintain the bending strength above acceptable limits or (2) increase the strengths to 
values greater than those seen with commercial bone cement formulations.  The 
number of cycles to failure at load levels that are defined percentages of the reference 
strength will be increased in specimens containing encapsulated OCA, indicating 
repair of microcracks in response to cyclic loading.   
 
Specific Aim 4: Perform preliminary evaluations of the in vitro cytotoxicity of the self-
healing PMMA formulation in comparison with commercial formulations.  In this aim, 
calcein AM and Hoechst 33342 staining will be used to assess viability of MG63 human 
osteosarcoma cells following exposure to commercial and capsule-embedded cement 
extracts.  Bone proliferation is also a common marker for biocompatibility; therefore, 
EdU staining will be used to determine if cement leachables interfere with progression 
through the cell cycle.  Response of cells to the healing agent alone (OCA) will also be 
investigated. 
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Hypothesis 4: Viability and proliferation of MG63 cells exposed to extracts from the 
capsule-embedded formulation will not be significantly different from the viability 
and proliferation of cells exposed to extracts from commercial PMMA bone cement 
formulations.  OCA may affect cell viability and proliferation but only at 
concentrations much higher than what can be expected from this composite in vivo. 
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2. Chapter 2: Microencapsulation of 2-octyl 
cyanoacrylate tissue adhesive for self-healing acrylic 
bone cement 
The text and figures included in Chapter 2 were previously published in the 
October 2012 edition of the Journal of Biomedical Materials Research Part B: Applied 
Biomaterials.  The full citation for the article is: Brochu Alice BW, Chyan WJ, Reichert 
WM. 2012. Microencapsulation of 2-octylcyanoacrylate tissue adhesive for self-healing 
acrylic bone cement. J Biomed Mater Res Part B 2012:100B:1764–1772.  John Wiley & 
Sons Ltd. does not require permission for authors to reuse their own articles, but an 
optional grant of license can be obtained and is included in Appendix B. 
 
2.1 Chapter synopsis 
This chapter describes the first phase of developing a self-healing acrylic bone 
cement: the preparation and characterization of polyurethane microcapsules containing 
a medical cyanoacrylate tissue adhesive.  Capsules were prepared by interfacial 
polymerization of a toluene-2,4-diisocyanate-based polyurethane prepolymer with 1,4-
butanediol to encapsulate 2-octyl cyanoacrylate.  Various capsule characteristics, 
including: resultant morphology, average size and size distribution, shell thickness, 
content and reactivity of encapsulated agent, and shelf life are investigated and their 
reliance on solvent type and amount, surfactant type and amount, temperature, pH, 
agitation rate, reaction time, and mode of addition of the oil phase to the aqueous phase 
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are presented.  Capsules had average diameters ranging from 74 to 222 µm and average 
shell thicknesses ranging from 1.5 to 6 µm.  The capsule content was determined via 
thermogravimetric analysis and subsequent analysis of the capsules following up to 8 
weeks storage revealed minimal loss of core contents.  Mechanical testing of OCA-
containing capsules showed individual capsules withstood compressive forces up to a 
few tenths of Newtons, and the contents released from crushed capsules generated 
tensile adhesive forces of a few Newtons.  Capsules were successfully mixed into the 
poly(methyl methacrylate) bone cement, surviving the mixing process, exposure to 
methyl methacrylate monomer, and the resulting exothermic matrix curing.   
 
2.2 Introduction  
The terms “healing” and “biomaterials” are most commonly linked through the 
tissue response to the presence of an implant[146].  Ratner has coined the expression 
“biomaterials that heal” to describe biomaterials that actively promote wound healing as 
opposed to those aimed at passivity or inertness[147].  While the biology and chemistry of 
healing have significant impacts on biomaterial performance, biological healing does not 
address the physical repair of biomaterials that experience mechanical and chemical 
breakdown as they are subjected to loading and degradation effects in vivo.  Developing 
synthetic biomaterials with the intrinsic ability to autonomously repair mechanical and 
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chemical damage is particularly important for implants that replace tissues also capable 
of self-repair[148, 149].  
Self-healing materials are a rapidly emerging class of composites with 
applications intended for use in the civil, mechanical, electrical, and aerospace 
industries.  These materials hold the potential for significantly extending material 
lifetimes by preventing and repairing failures caused by accumulated micro-damage 
due to microcrack formation.  To date, the majority of the research conducted on self-
healing bulk materials has employed composites, adhesives, and cements intended for 
traditional engineering applications[63-70].  The most broadly reported self-healing scheme 
is that pioneered by White and Sottos et al. in which a polymer matrix is co-embedded 
with a catalyst and microcapsules containing a reactive healing agent.  Once 
encountered by a propagating microcrack, the capsule shell ruptures, releasing the 
healing agent into the crack plan and exposing it to the catalyst embedded in the matrix.  
In situ curing of the healing agent ensues, halting crack propagation[47, 63-65, 71-73].  
The fixation of total joint replacements with acrylic bone cement is employed in 
hundreds of thousands of patients each year[18].  Poly(methyl methacrylate) (PMMA) 
bone cement is a space-filling matrix that forms mechanical interlocks between the stem 
of the implant and the surrounding boney tissue[9, 10].  Bone cement consists of two 
components: low molecular weight PMMA powder containing an initiator (e.g. benzoyl 
peroxide), and liquid methyl methacrylate (MMA) monomer.  Mixing the two 
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components in situ forms a slurry that initiates polymerization yielding a workable 
dough that is applied to the implant and hardens into a solid mass after the implant is 
inserted into the boney tissue[9].   While broadly successful, cemented implants are 
subject to failure following prolonged exposure to the harsh environment of the body as 
well as the cyclic loading patterns seen in vivo.  Microcrack formation and the generation 
of wear debris from both the articulating surfaces and the bone cement itself serve to 
accelerate wear that often leads to subsequent failure of the implant[18, 20, 25-28]. 
Due to its long history of use, lack of post-polymerization modifications, and 
need for improvement, the development of a self-healing PMMA bone cement is a very 
attractive option for the first self-healing biomaterial designed with the aforementioned 
embedded capsule and catalyst approach.  However, none of the existing self-healing 
systems are suitable for in vivo deployment due to reagent toxicity and/or inability to 
cure under aqueous conditions.  The production of a clinically acceptable PMMA-based 
acrylic bone cement containing a microencapsulated non-toxic healing agent is a logical 
starting point.   
2-octyl cyanoacrylate (OCA) tissue adhesive is water-reactive, FDA-approved, 
and currently employed in sutureless surgeries and external wound closure systems[47, 
145] and is therefore a strong candidate for the biocompatible monomer healing agent in a 
self-healing biomaterial.  By selecting OCA as the healing agent of interest, the 
aforementioned self-healing material design is simplified because no catalyst will need 
 42 
to be embedded within the material matrix; the released cyanoacrylate would be 
polymerized by ambient moisture permeating the bone cement matrix from the 
surrounding tissue. 
Polyurethane (PUR) is widely used in biomaterials due to its blood compatibility 
and its ability to be engineered to have a wide range of mechanical properties through 
the selection of various soft and hard segments[150-153].  Polyurethane capsules have 
previously been generated via interfacial polymerization of a variety of isocyanates and 
polyols using numerous emulsion characteristics.  Encapsulated agents include 
pesticides[154, 155], oils and organic solvents[156-161], drugs and proteins such as ibuprofen, 
ovalbumin, and isoniazid[162-164], and various dyes[152].  Microcapsules of toluene-2,4-
diisocyanate (TDI)-based polyurethane have been shown to be both robust and capable 
of containing a water-reactive monomer for self-healing applications[165], which we 
found attractive.  
In the current study we present the first phase of the development of a self-
healing PMMA bone cement: the encapsulation of OCA within PUR microcapsules.  The 
average capsule size and size distribution, capsule shell thickness, content and reactivity 
of encapsulated agent, and shelf life of these capsules were studied and preliminary 
experiments have been performed to incorporate these capsules into a bone cement 
matrix to assess their process survivability for future testing of a biocompatible self-
healing composite. 
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2.3 Experimental section 
2.3.1 Materials 
Unless otherwise specified, materials were obtained from commercial suppliers 
and used without further purification.  OCA was generously donated by Ethicon, Inc., 
Raleigh, NC 27616.  Acetone, methyl ethyl ketone (MEK), diethyl ketone (DEK), methyl 
isobutyl ketone (MIBK), and cyclohexanone (Sigma Aldrich) were used as solvents and 
TDI and 1,4-butanediol (1,4-BD) (Sigma Aldrich) were used to synthesize the 
polyurethane prepolymer (pPUR) following the protocol outlined by Yang et al[165].  
Pluronic F-68 (Sigma Aldrich) was used as a surfactant.  Para-toluenesulfonic acid 
monohydrate (Sigma Aldrich, PTSA) was added to the organic phase as a monomer 
stabilizer.  Commercially available bone cement (Biomet Cobalt G-HV High Contrast 
bone cement) was used in the preliminary bone cement matrix experiments. 
 
2.3.2 Preparation of polyurethane prepolymer 
A TDI prepolymer was prepared for use in the microencapsulation procedure by 
scaling up the protocol reported by Yang et al[165].  Briefly, TDI (109.25 g) was dissolved 
in cyclohexanone (750 mL) in a 3-necked round bottom flask.  The mixture was 
suspended in an oil bath at 80 ºC and agitated with a magnetic stirrer.  1,4-BD (20.315 
mL) was slowly added to the stirring TDI/cyclohexanone solution at a rate of 2 mL/min 
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and then the flask was purged with N2 and allowed to react for 24 h.  Following this 
reaction time, the mixture was distilled at 100 ºC under vacuum for 4-5 h to remove the 
excess cyclohexanone, water, and TDI from the system.  A viscous yellow polyurethane 
prepolymer remained in the flask following the completion of this process.  Gel 
permeation chromatography analyses were performed with a Varian Prostar Model 210 
pump, a Varian Prostar Model 320 UV/Vis detector set to 254 nm detection, a Wyatt 
Dawn EOS multi-angle light scatterer, Wyatt QELS (quasi-electric light scattering), 
Wyatt Optilab DSP Interferometric Refractometer (RI), and a series of two Agilent 
Technology PL gel columns (7.5 X 300mm, 1 79911GP-503 (103Å) and 1 79911GP-504 (104 
Å)) in tetrahydrofuran at 22 ºC.  Molecular weights were calculated using a dn/dc value 
of 0.108 mL/g calculated from solutions of known concentration using the dn/dc 
calibration mode of the Wyatt Technology ASTRA software version 5.3.2.16.  The 
polydispersity index of the prepolymer was found to be 1.23, which was comparable to 
the value of 1.33 reported by Yang et al[165]. 
 
2.3.3 Preparation of microcapsules 
At room temperature, Pluronic F-68 surfactant (1.84 g) was dissolved in 
deionized water (90 mL) in a 250 mL beaker.  The solution was agitated for 1 h with a 
digital mixer (VWR PowerMax Elite Dual-Speed Mixer) before beginning the 
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encapsulation procedure.  The aqueous phase was suspended in a hot water bath and 
heated to 40 ºC prior to the addition of the organic phase and chain extender. 
To prepare the organic solutions, the pPUR (3 g) was dissolved in MEK (10 mL) 
at room temperature.  OCA (4 mL) was dissolved in MIBK (8 mL) separate from the 
pPUR solution.  PTSA (1%) was dissolved in the MIBK phase to further stabilize the 
OCA monomer.  The pPUR and OCA solutions were added simultaneously to the 
aqueous phase but not mixed prior to this addition.  After the organic and aqueous 
phases were combined, 1,4-BD (3 mL) chain extender was added dropwise to the stirring 
mixture via a syringe to form the segmented PUR shell material consisting of hard TDI-
based segments and soft 1,4-BD segments.  After a reaction time of 2 h, the agitator was 
switched off, the suspension of microcapsules rinsed with deionized water, and vacuum 
filtered. 
 
2.3.4 Characterization of microcapsules 
2.3.4.1 Capsule morphology, size, and shell thickness 
A vacuum sputter coater (Denton Desk IV) was used to deposit a 10 nm layer of 
gold onto the microcapsule samples for scanning electron microscope (SEM) imaging.   
The surface morphology of the capsules was examined and average capsule diameters 
and shell thicknesses were also measured. 
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2.3.4.2. Characterization of capsule content and reactivity 
Following the vacuum filtering and drying of the capsules, samples were taken 
and examined under a stereoscope (Bausch & Lomb).  Capsules were sliced open with a 
scalpel and release of their liquid contents observed.  Capsules were then crushed 
between two glass coverslips to qualitatively assess their bonding ability.   
Thermogravimetric analysis (TA Instruments Q500 v6.7, TGA) was used to 
quantitatively analyze the capsule contents as well as the shelf life of the capsules.  Small 
amounts (< 10 mg) of each sample were heated from 25 to 650 ºC at a rate of 10 ºC/min 
under N2 environment until all of the material was vaporized.  Comparisons were made 
between the decomposition rates of pure PUR shell, pure OCA healing agent, pure 
MIBK solvent, and capsules containing healing agent fabricated under various 
conditions to approximate the content of the capsules.   Samples were also tested after 
various storage times to assess capsule shelf life.   
 
2.3.4.3 Compression testing of individual microcapsules 
The compressive strength of single microcapsules was measured using a 
dynamic mechanical analyzer (TA Instruments RSA-G2 solid analyzer, DMA).  This 
approach was adapted from a procedure described elsewhere[165, 166] that employed a 
single capsule compression apparatus to examine the mechanical response of 
microcapsules.  A single capsule was placed on the lower DMA compression plate and 
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the presence of a single capsule on the testing plate was verified by performing sample 
loading under a stereoscope.  Displacement of the upper DMA plate was applied at a 
constant rate of 5 µm/s until shell compressive failure was observed. 
 
2.3.4.4 Adhesion testing of crushed microcapsules 
Microcapsules containing OCA were crushed between two aluminum plates (8 
mm diameter) using a Tinius Olsen 1000 Universal Testing Machine.  The contents were 
allowed to cure at room temperature for 1.5 h, thus gluing the plates together.  The 
detachment force necessary to break the bond between the upper and lower plates was 
recorded.  The adhesive forces measured for Loctite® Super Glue (ethyl 2-
cyanoacrylate), monomer OCA, monomer OCA dissolved in MIBK, crushed empty 
capsules, and crushed empty capsules manually mixed with OCA were used as negative 
and positive controls. 
 
2.3.4.5 Incorporation of capsules into a PMMA matrix 
Biomet Cobalt G-HV High Contrast bone cement kits were obtained from the 
Duke University Medical Center.  The powder component of the bone cement (10 g) was 
mixed with the liquid monomer (4.7 g) according to the manufacturer’s instructions.  
PUR capsules (1 g) were added to the PMMA dough and vigorously stirred to disperse 
the capsules within the matrix material.  The cement dough was shaped into small disks 
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and cured for 1 h.  Small samples of the resulting composites were broken from the 
polymerized disks and analyzed under a stereoscope as well as via SEM to visualize the 
embedded capsules and estimate the fraction that remained intact. 
 
2.4 Results 
2.4.1 Reaction conditions 
2.4.1.1 Organic solvents 
Numerous solvents have been used in PUR microcapsule formation to 
encapsulate drugs, pesticides, oils, organic solvents, and various dyes[159, 160, 165, 167].  
Several organic solvents were considered for the organic phase.  The majority of these 
solvents were eliminated either because they failed to dissolve the pPUR (octanol, 
valeric acid, hexane, cyclohexane, butanol, toluene, dichloromethane, ethyl acetate, 
xylene, and ethyl ether) and/or had toxicity concerns (chlorobenzene, cyclohexanone, 
and tetrahydrofuran).  Acetone and acetic acid were eliminated for being too miscible 
with water.  Following these broad solvent eliminations, only MEK, DEK, and MIBK 
remained from the original group of potential solvents.  MIBK was selected as the 
solvent for OCA and PTSA because its solubility in water is lower than that of MEK and 
DEK.  However, the pPUR was not soluble in DEK or MIBK; therefore, MEK was 
selected as the solvent for pPUR. 
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2.4.1.2 Surfactants 
Several emulsifying surfactants were also considered[162-164].  Tergitol NP-10, Myrj 
52, Brij 52, Tween 20, Tween 65, sodium dodecyl sulfate, and poly(styrene-co-maleic 
anhydride) were eliminated because they were unable to create a stable emulsion, 
resulting in a solid mass of polymer.  Poly(vinyl alcohol) resulted in the formation of 
capsules, but was eliminated because it appeared to react with the OCA monomer.  
Gum arabic was eliminated because it resulted in the formation of both capsules and 
solid spheres.  Pluronic F-68 was selected because it consistently yielded spherical 
capsules of uniform size, density, and smooth surface morphology. 
 
2.4.1.3 Temperature 
Reactions carried out at room temperature (25 ºC) and 40 ºC produced capsules 
with similar spherical morphology and smooth capsule characteristics, however, 
increased temperature resulted in decreased average diameter and narrower capsule 
size distribution (342 ± 99 µm at 25 ºC versus 220 ± 74 µm at 40 ºC at 500 rpm agitation 
rate).  Reactions performed at 70 ºC yielded a polymer mass within the reaction vessel 
rather than capsules.  A reaction temperature of 40 ºC was selected because smaller 
capsules are more ideal when considering the effects of their inclusion on the mechanical 
properties of the matrix.  Furthermore, the increased temperature should serve to 
enhance the rate of interfacial polymerization. 
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2.4.1.4 Controlling OCA reactivity 
The reactivity of the OCA was reduced by adding 1% PTSA to the organic phase.  
PTSA dissociates into H+ and a tosylate anion that is stable with the OCA monomer and 
should not initiate anionic polymerization. The addition of PTSA eliminated the 
formation of residual polymer seen on the blades of the agitator, enhanced the adhesion 
of capsules crushed between two glass slides, and resulted in capsules that were 15-25% 
smaller than those made without PTSA.  
To minimize interactions between the OCA and the pPUR prior to encapsulation, 
separate organic pPUR and OCA solutions were prepared and added to the aqueous 
phase simultaneously at the same rate using 25 mL pipets.  This mode of addition 
resulted in increased uniformity of the size, shape, and surface morphology of resulting 
capsules. 
 
2.4.2 Effect of agitation rate 
The average diameters of the microcapsules were measured for a range of 
agitation rates (impellor speed of 350-1100 rpm) while all other reaction conditions were 
held constant.  Figure 2.1A is a double-y plot of microcapsule diameter and shell 
thickness as a function of agitation rate.  Similar results were also reported for urea-
formaldehyde capsules containing dicyclopentadiene[168] and PUR capsules containing 
isophorone diisocyanate[165].  Increasing agitation rate from 350 to 1100 rpm decreased 
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the average capsule diameter from 222 ± 56 µm to 74 ± 19 µm, and decreased the capsule 
shell thickness from 6.3 ± 2.6 µm to 1.6 ± 0.5 µm, although both appeared to reach 
asymptotes with increasing agitation rate (numbers given as average ± one standard 
deviation of at least 200 diameter and 15 shell thickness measurements).  Figure 2.1B is 
an SEM image of microcapsules made at 700 rpm.  The ratio of shell thickness to shell 
diameter also remained remarkably consistent from 350 to 1100 rpm, ranging from 0.01 
to 0.02. 
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Figure 2.1: (A) Increasing agitation rate results in decreasing average capsule diameter 
and average shell thickness; (B) smooth surface morphology of microcapsules made at 
700 rpm is clearly visible under SEM. 
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2.4.3 Capsule thermal properties 
TGA was used to determine the composition of the OCA-containing PUR 
microcapsules by comparing the thermal properties of the intact microcapsules made at 
various agitation rates with samples of the pure OCA monomer, pure MIBK solvent, 
and pure PUR shell wall material.  Figures 2.2A and 2.2B present the weight loss and 
derivative of weight loss for these samples at increasing temperatures.  MIBK and OCA 
showed sharp vaporization curves, with samples completely vaporized by 78 ºC and 255 
ºC respectively.  The pure PUR shell wall material and OCA-containing microcapsules 
demonstrated more prolonged and multi-phased vaporization curves.  The pure shell 
material rapidly loses about 50% of its weight between 200 ºC and 325 ºC while the 
remainder was lost more gradually between 325 ºC and 650 ºC.  These two distinct 
phases may be attributed to the degradation of the PUR soft (1,4-BD) and hard (TDI) 
segments respectively.    
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Figure 2.2: TGA results provide thermal degradation behaviors of capsules made 
under various conditions.  The weight loss curves of capsules as well as pure samples 
of MIBK, OCA, and PUR shell material are shown in (A).  Derivatives of the TGA 
data for capsules, MIBK, OCA, and PUR shell material are presented in (B).  All 
experiments were conducted at a heating rate of 10 ºC/min under N2. 
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The TGA graphs of the weight loss and derivative weight loss of OCA-
containing microcapsules fabricated at agitation rates ranging from 350 to 1100 rpm are 
also shown in Figures 2.2A and 2.2B.  Note that these traces exhibit the same multi-
phasic behavior of the pure shell material, but are initiated at lower temperatures due to 
the presence of core OCA material.  The weight percentages of the core and shell 
components in the various capsule types were estimated based on analysis of the TGA 
data as described previously[165].  Figure 2.3 shows the weight percentages of MIBK, 
OCA, and PUR shell for the intact capsules as a function of agitation rate.  The OCA 
content in the core decreased from 58% in capsules made at 350 rpm to 46% in capsules 
made at 1100 rpm while the shell content increased correspondingly from 37% to 47%.  
Note: the presence of MIBK was consistently less than 7% in capsules made at all 
agitation rates. 
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Figure 2.3: TGA data analysis was used to determine the various weight fractions of 
components of the microcapsules. 
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Figure 2.4 shows the TGA curves of OCA-containing microcapsules made at 700 
rpm that were stored at room temperature for up to 8 weeks in sealed glass scintillation 
vials.  A 4.9% reduction in the core content was observed over a 14 day storage period 
with a total reduction of 6.6% seen following 56 days of storage. 
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Figure 2.4: TGA weight loss curves of microcapsules made at 700 rpm following 56 
days of storage. 
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2.4.4 Capsule mechanical properties 
Stress-strain curves of individual OCA-filled microcapsules compressed at 
constant rate of 5 µm/s are shown in Figure 2.5.  For all samples, the load increased 
monotonically in response to a constant compression rate until reaching failure at a 
maximum load.  The inset is an SEM image of a typical compression-failed microcapsule 
post-fracture.  The largest and thickest-walled microcapsules showed the greatest 
malleability, and the thinnest-shelled capsules demonstrated the lowest compressive 
strength. 
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Figure 2.5: Stress-strain curves of microcapsules fabricated at various agitation rates.  
All compressions performed at a rate of 5 µm/s.  Following capsule shell failure, the 
capsule was removed from the lower DMA compression plate, transferred to carbon 
tape on an SEM stage, gold-coated, and then imaged.  (Inset) An SEM image of a 
capsules post-DMA testing where the failure plane is clearly visible; the original 
capsule diameter was 180 µm. 
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Normalizing the DMA data shown in Figure 2.5 to microcapsule equatorial 
cross-sectional area yields the compressive strengths listed in Table 2.1.  As both the 
shell and liquid contents contribute to the mechanical properties of the capsules, 
variations in the percent fill of the capsules could play a significant role in the maximum 
loads that can be borne by those capsules and account for some of the observed 
variability.  An increase in microcapsule stiffness with increasing compression rate used 
during testing was also observed (data not shown), possibly due to viscous 
contributions from the fluid-filled core.  A decrease in the strain at failure was also 
observed in capsules fabricated at higher agitation rates. 
 62 
Table 2.1: Mechanical properties of single capsules (data presented as average ± one 
standard deviation) 
Agitation rate (rpm) t (µm) σmax (MPa) ε at failure (%) 
500 2.88 ± 1.5 13.63 ± 1.44 20.8 ± 0.2 
700 1.42 ± 0.3 6.71 ± 0.79 10.4 ± 3.1 
900 1.65 ± 0.5 9.38 ± 1.95 10.6 ± 0.9 
1100 1.60 ± 0.5 8.33 ± 2.25 8.1 ± 0.8 
 
 63 
To quantify the adhesive properties of the encapsulated healing agent, capsules 
fabricated at 700 rpm were crushed between two aluminum plates.  The detachment 
force necessary to separate the bonded upper and lower plates is presented in Table 2.2 
for microcapsules along with values for the pure adhesive positive controls and empty 
capsule negative controls.  Crushed empty microcapsules showed no detachment force, 
while crushed OCA-containing microcapsules exhibited nearly the same detachment 
force as crushed empty capsules manually mixed with adhesive, but considerably less 
detachment force than the adhesives alone. 
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Table 2.2: Detachment forces required to separate aluminum plates bonded by 
various cyanoacrylate (data presented as average ± one standard deviation) 
Material Detachment force (N) 
Adhesives 
Loctite® Super Glue 
Pure OCA 
OCA dissolved in MIBK 
 
546 ± 112 
108 ± 18 
40.8 ± 1.7 
Crushed microcapsules 
Empty microcapsules 
Empty microcapsules + Loctite® Super Glue 
Empty microcapsules + OCA 
OCA-containing microcapsules 
 
0 ± 0 
7.6 ± 1.4 
5.1 ± 0.4 
4.4 ± 0.8 
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2.4.5 Incorporation of capsules into the PMMA matrix 
OCA-filled microcapsules fabricated at 500 rpm were added to Biomet Cobalt G-
HV High Contrast bone cement and mixed, cast, cured, and fractured as described 
above.  Figure 2.6A shows an SEM image of intact microcapsules distributed throughout 
the PMMA matrix.  The crack plane of a PMMA specimen containing 30 wt% capsules is 
shown in Figure 2.6B; capsules fractured by the damage event are clearly visible in this 
plane as well as in Figure 2.6C, a magnified SEM image of a ruptured microcapsule.  A 
scan of fractured planes indicates that roughly 40% of the capsules remained intact 
following the damage event. 
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Figure 2.6: (A) An SEM image of PMMA bone cement containing intact 
microcapsules, (B) a PMMA fracture plane in which ruptured capsules are visible, and 
(C) a magnified image of a fractured microcapsule within the damage plane of the 
matrix. 
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2.5 Discussion 
The OCA-containing PUR capsules described here represent a new embedded 
catalyst-free self-healing system with biomedical applications.  The optimization of the 
encapsulation protocol relied on the identification of the proper emulsion conditions 
with respect to variables such as solvent, surfactant, and temperature.  The primary 
concerns were improper solvent miscibility, insufficient stability of the o/w interface, 
interaction between the OCA and other emulsion components, and reaction 
temperature.  While a number of options were considered and investigated, the final 
conditions using MEK and MIBK as solvents, Pluronic-F68 as the surfactant, and a 
reaction temperature of 40 ºC were selected.   
The average diameter of the microcapsules was influenced by various factors 
including the fluid mechanics associated with the mixing apparatus, viscosity of the 
emulsion, the characteristics of the surfactant used, the agitation rate, and the 
temperature of the emulsion[165].  As the agitation rate was increased, the oil phase was 
emulsified into smaller droplets upon its introduction to the aqueous phase.  Variability 
in capsule contents was observed though most can be attributed to variations in solvent 
content.  Capsules were all tested day 1 post-fabrication and were thoroughly dried 
before all TGA procedures were performed so losses in weight at less than 78 ºC are 
most likely due to loss of MIBK rather than loss of surface moisture; the change in 
weight between 78 and 100 ºC was minimal in capsules made at all agitation rates, 
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suggesting little to no water is present in or on the capsules at day 1.  Differences in the 
shell content of the capsules determined from TGA (Figure 2.3) correlated with the small 
variations in the ratio of shell thickness to capsule diameter for capsules made at higher 
agitation rates; i.e. the slightly higher t/d values for capsules made at 900 and 1100 rpm 
(0.02 versus 0.01) indicate that a larger weight percent of those capsules is composed of 
shell material.   
It is interesting to note that at 110 ºC, the upper end of the PMMA 
polymerization exotherm[169], there is little mass loss seen in capsules with low MIBK 
content (500 and 900 rpm), indicating that capsules will survive the temperatures 
associated with matrix polymerization (Figure 2.2A).  This observation was later 
supported by the successful incorporation of the capsules into a PMMA matrix (Figure 
2.6).  However, temperature is not the only factor that will come into play when 
assessing the process survivability of the capsules[47] and these observations merely 
confirm the feasibility of the material design concept.   
To be implemented successfully, these capsules must retain their self-healing 
capability for a significant percentage of the lifetime of the implant.  Even though TGA 
data showed a 4.9% decrease in core content over 2 weeks of storage time, this could be 
partially attributed to the diffusion and subsequent evaporation of MIBK through the 
capsule shell.  At day 14, only 0.4% of capsule weight was lost prior to 78 ºC, bolstering 
the hypothesis that solvent evaporation is the main cause in the decrease of capsule core 
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content during that time frame.  Testing of the capsules after 56 days dry storage 
indicates minimal change in the capsules over that time as a majority of the MIBK 
evaporated during the first 2 weeks of storage.  The rightward shift in the TGA curve 
over time could be explained by slow polymerization of the encapsulated OCA 
monomer by infiltrating moisture.  In a previous study, Yang et al. reported a loss in 
core contents of 7.9 and 8.6 wt% of PUR capsules containing isophorone diisocyanate 
following 3 and 6 months storage[165].  The decreases presented here are comparable to 
these rates of mass loss.  Future TGA analysis will be performed to determine if the loss 
of core material continues to be marginal over longer storage times.  Shelf life studies 
following capsule storage in water, an environment more relevant for this application, 
are also underway.   
Other groups have reported single microcapsule compression testing using a 
modified load frame[165, 166] to gather information on the mechanical properties of the 
shell material.  In the current study, compression testing showed the larger 
microcapsules to be more malleable; the compressive stress also decreased with 
decreasing shell thickness.  The strain at failure decreased with increasing agitation rate 
and increasing PUR content, suggesting the OCA core contributes to the malleability of 
the capsules.  Loads born by smaller microcapsules made at 900 and 1100 rpm were very 
similar (Figure 2.5) as expected given the similarities between the average diameters and 
shell thicknesses of microcapsules made at these rates.   
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Bulk polyurethane elastomers typically show MPa strengths and stiffnesses[170]; 
however, there is some uncertainty in the literature about how to calculate single 
microcapsule strength and stiffness.  When normalized to equatorial shell cross-sectional 
area only, as reported previously[165], our microcapsules showed GPa strengths and 
stiffnesses, which are extremely high for an elastomer such as 1,4-BD-extended TDI.  
When normalized to the full equatorial cross-sectional area of the shell plus the core, the 
microspheres showed both MPa strengths and stiffnesses that are consistent with bulk 
elastomers.  This makes sense since both the OCA core material and the shell contribute 
to microcapsule mechanical properties.      
Detachment force studies were conducted to provide a quantitative measure of 
the adhesive capability of crushed OCA-containing microcapsules.  Pure OCA tissue 
adhesive exhibited a detachment force of approximately 100 N that was 20% that of pure 
Loctite® Super Glue, indicating that OCA is a weaker adhesive.  Dissolving OCA in 
MIBK, as used in the encapsulation process, weakened the average detachment force to 
approximately 40 N.  Crushed OCA-containing microcapsules and crushed empty 
microcapsules mixed with OCA or Loctite® Super Glue exhibited detachment forces of 
4-8 N.  As expected, crushed empty microcapsules exhibited no detachment force.  
The OCA-containing microcapsules clearly possessed bonding capability, albeit 
much weaker than the pure adhesive.  Samples of crushed OCA-containing 
microcapsules removed from between the aluminum plates were composite patties of 
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bonded microcapsule fragments.  This same patty formation was observed with crushed 
empty microcapsules manually mixed with OCA or Loctite® Super Glue; however, 
crushing of empty capsules resulted in an unbonded powder of broken PUR shell 
fragments.  This indicates that the released or added adhesive was more effective in 
forming a composite of shell fragments and polymerized OCA than it was in bonding 
the aluminum plates together.  It should be noted, however, that compression testing 
and detachment force testing are considerably different measures of microcapsule 
functionality and not necessarily a good indicator of how microcapsules may perform in 
halting the progression of microcracks within the PMMA matrix.  
The next phases of this project will focus on (1) optimizing the microcapsule 
preparation protocol and investigating the effects of capsule inclusion on the bulk 
mechanical properties of PMMA, (2) characterizing the fracture toughness and self-
healing functionality of the system, and (3) investigating the biocompatibility of the 
microcapsule-embedded bone cement compared with commercial formulations.  
 
2.6 Conclusions 
This chapter summarizes the first report of encapsulated OCA with adhesive 
capability, which supports the feasibility of our self-healing biomaterial design.  OCA-
containing PUR microcapsules possessing regular, spherical morphology were created 
via interfacial polymerization of a TDI-based polyurethane prepolymer with a small 
 72 
chain diol.  Capsules with average diameters ranging from approximately 75-220 µm 
were made at agitation rates of 350-1100 rpm.  Average capsule diameter and shell 
thickness both decreased with increasing agitation rate; however, a consistent wall 
thickness to diameter ratio of 0.01-0.02 was observed throughout.  Core content 
comprised more than half of the microcapsule volume at all agitation rates with little 
weight loss after 8 weeks of storage.  Individual capsule compression tests showed that 
larger microcapsules were more malleable and microcapsule strength was influenced by 
shell thickness.  Crushed OCA-containing capsules possessed bonding capability that 
was diminished due to the presence of capsule debris that interfered with the ability of 
the glue to bond between the two testing surfaces. 
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3. Chapter 3: Mechanical testing of acrylic bone cement 
embedded with microencapsulated 2-octyl 
cyanoacrylate 
Sections of the text and figures included in Chapter 3 were recently accepted for 
publication in the Journal of Biomedical Materials Research Part B: Applied 
Biomaterials.  The full citation for the article is: Brochu Alice BW, Evans GA, Reichert 
WM. 2013. Mechanical and cytotoxicity testing of acrylic bone cement embedded with 
microencapsulated 2-octyl cyanoacrylate. J Biomed Mater Res Part B 2013.  This article 
does not yet have a publication date; however, John Wiley & Sons Ltd. does not require 
permission for authors to reuse their own articles, but an optional grant of license will be 
obtained as soon as one is available.  Please note that this manuscript described the work 
for Specific Aims 2 and 4 and was in to two chapters for this dissertation to maintain 
parallel structure with the Specific Aims. 
 
3.1 Chapter synopsis 
The water-reactive tissue adhesive 2-octyl cyanoacrylate (OCA) was 
microencapsulated in polyurethane shells and incorporated into Palacos R bone cement.  
The tensile and compressive properties of the composite material were investigated in 
accordance with commercial standards and fracture toughness of the capsule-embedded 
bone cement was measured using the tapered double-cantilever beam (TDCB) geometry. 
Incorporating up to 5 wt% capsules had little effect on the compressive and tensile 
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properties of the composite, but greater than 5 wt% capsules reduced these values below 
commercial standards.  Fracture toughness was increased by 13% through the 
incorporation of 3 wt% capsules and eventually decreased below the toughness of the 
capsule-free controls at capsule contents of 15 wt% and higher; fracture toughness 
remained within the literature-reported range for all capsule contents tested.  Overall, 
the addition of lower wt% of OCA-containing microcapsules to commercial bone cement 
was found to moderately increase static mechanical properties of the material. 
 
3.2 Introduction 
Self-healing materials (SHM) are a rapidly emerging class of materials that 
prevent failure through the autonomous repair of microdamage in situ.  One of the most 
broadly reported SHMs is the matrix repolymerization scheme pioneered by White and 
Sottos et al. in which a polymer matrix is co-embedded with catalyst and microcapsules 
containing a reactive healing agent[47, 63, 65, 71-73, 171].  Upon encountering a propagating 
microcrack, the microcapsule shell ruptures and releases the healing agent into the crack 
plane, exposing it to the catalyst embedded in the matrix.  In situ curing of the healing 
agent ensues, halting crack propagation. 
Numerous implants fail due to fatigue, wear, and environmental cracking 
following the accumulation of microdamage[27, 47, 172-175], marking these biomaterials as 
potential candidates for the introduction of self-healing biomaterials; however, there has 
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been very little discussion of extending SHM into biomaterials.  Consequently, none of 
the existing SHM systems currently under development employ materials and reagents 
acceptable for in vivo load-bearing applications.  Furthermore, no SHM have been tested 
under conditions that simulate the in vivo environment. 
Due to its long history of use, ease of fabrication, and susceptibility to fatigue, 
acrylic bone cement is an attractive candidate for the first self-healing biomaterial based 
on the matrix repolymerization approach to self-healing[47, 77, 84, 171].  Acrylic bone cement 
is a space-filling matrix that forms mechanical interlocks between the metallic stem of a 
total joint replacement and the surrounding boney tissue[10], serving to transfer loads 
from the prosthesis to the bone[11].  Bone cement is a two-component thermoset 
consisting of a low molecular weight poly(methyl methacrylate) (PMMA) powder 
containing an initiator (e.g. benzoyl peroxide), and liquid MMA monomer.  In situ 
mixing the two components initiates polymerization to yield a workable dough that is 
applied to the implant and hardens into a solid mass after the stem is inserted[8, 171].  
The total loading experienced by bone cement in vivo is a mixture of 
compressive, bending, tensile, shear, and torsional forces[90] and as such, procedures to 
determine the mechanical properties involve the application of various static or dynamic 
stresses.  Bone cements must adhere to static mechanical standards for tensile, 
compression, and fracture toughness testing before it is deemed suitable to investigate 
more biomimetic cyclic testing[90]. 
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Although the overall project aim is to develop a bone cement capable of self-
repair in response to damage, any new material proposed must also meet the standards 
required for the static mechanical properties of commercial formulations.  We recently 
reported the microencapsulation of OCA in polyurethane shells as well as the successful 
distribution and fracture of the capsules embedded in a commercial bone cement 
matrix[171].  Among candidate cyanoacrylates, OCA is an attractive healing agent for a 
self-healing biomaterial because it is widely used clinically[145, 176] and because its use 
would eliminate the need for the incorporation of a potentially toxic catalyst into the 
matrix; the catalyst for OCA polymerization would be ambient moisture from the 
surrounding tissue. 
The current study presents the first mechanical characterization of a biomaterial 
formulation consisting of OCA-containing microcapsules embedded in commercial 
PMMA bone cement.  Incorporating up to 5 wt% capsules had little effect on the 
compressive and tensile properties of the composite, but greater than 5 wt% capsules 
reduced these values below commercial standards.  Fracture toughness was increased 
by 13% through the incorporation of 3 wt% capsules and eventually decreased below the 
toughness of the capsule-free controls at capsule contents of 15 wt% and higher.  Overall 
the addition of lower wt% of OCA-containing microcapsules to commercial bone cement 
was found to moderately increase static mechanical properties of the material. 
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3.3. Experimental section 
3.3.1 Reagents 
Unless otherwise specified, materials were obtained from commercial suppliers 
and used without further purification.  OCA was generously donated by Ethicon, Inc., 
Raleigh, NC 27616.  Methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), and 
cyclohexanone (Sigma Aldrich) were used as solvents and 2,4-toluene diisocyanate (TDI) 
and 1,4-butanediol (1,4-BD) (Sigma Aldrich) were used to synthesize the polyurethane 
prepolymer (pPUR) following the protocol outlined by Yang et al. and reported by the 
authors previously[165, 171].  Pluronic F-68 (Sigma Aldrich) was used as a surfactant.  Para-
toluenesulfonic acid (Sigma Aldrich, PTSA) was added to the organic phase as a 
stabilizer for the OCA monomer.  Commercially-available Palacos R PMMA bone 
cement (Zimmer) was used for all experiments reported herein.     
 
3.3.2 Microcapsule preparation 
Microcapsules were prepared and characterized as described previously[171].  
Briefly, at room temperature, Pluronic F-68 surfactant (1.84 g) was dissolved in 
deionized water (90 mL) in a 250 mL beaker.  The solution was agitated for 1 h with a 
digital mixer (VWR PowerMax Elite Dual-Speed Mixer) before beginning the 
encapsulation procedure.  The aqueous phase was suspended in a hot water bath and 
heated to 50 ºC prior to the addition of the organic phase and chain extender. 
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OCA (4 mL) was dissolved in MIBK (8 mL) and pPUR (3 g) was dissolved in 
MEK (10 mL) separately at room temperature.  PTSA (1%) was added to the OCA-MIBK 
solution to further stabilize the OCA monomer.  The pPUR- and OCA-containing 
solutions were then added simultaneously to the aqueous phase but not mixed prior to 
this addition.  After the organic and aqueous phases were combined, the 1,4-BD (3 mL) 
chain extender was added dropwise to the stirring mixture via a syringe to form the 
segmented PUR shell material consisting of hard TDI-based segments and soft 1,4-BD 
segments.  After a reaction time of 2 h at an agitation rate of 700 rpm, the mixer was 
switched off and the suspension of microcapsules rinsed with deionized water and 
vacuum filtered.  Capsules were air-dried prior to use in the following experiments[171]. 
 
3.3.3 Preparation of capsule-containing bone cement samples 
The powder and liquid components of the bone cement were mixed according to 
the manufacturer’s instructions[177], OCA-containing capsules were added to the slurry, 
and the resultant material was added to molds to form the desired specimen shape.  
Samples were cured in the molds for at least 1 h, released, and smoothed with 240 mesh 
silicon carbide to conform to the specified geometrical requirements.  The wt% of OCA-
containing capsules in the bone cement composites ranged from 0-40 wt% where the 
wt% of total particulates (OCA capsules plus PMMA powder) was held constant at 67 
wt% in all specimens. 
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3.3.3.1 Tensile testing of capsule-embedded bone cement 
Following ASTM D638, bone cement specimens were cured in “dog bone”-
shaped silicone rubber molds for 1 h and then smoothed, producing specimens with 
midsection dimensions of 13 ± 0.5 mm by 3.2 ± 0.4 mm (Figure 3.1A).  24 h post-
manufacturing, specimens were subjected to uniaxial tensile testing at a cross-head 
speed of 5 ± 1 mm/min until failure using a Tinius Olsen 1000 Ultimate Testing Machine.  
All tests were performed in air at RT.  The ultimate tensile strength (UTS) was calculated 
as the force at failure divided by the cross-sectional area measured for each sample. 
 
3.3.3.2 Compression testing of capsule-embedded bone cement 
Following ASTM F451, bone cement specimens were cured in a 
polytetrafluoroethylene mold for 1 h and smoothed, yielding cylindrical specimens with 
a diameter of 6 ± 0.1 mm and height of 12 ± 0.1 mm (Figure 3.1B).  24 h post-fabrication, 
specimens were subjected to uniaxial compression testing at a cross-head speed of 20 
mm/min using a Tinius Olsen 1000 Ultimate Testing Machine.  All tests were performed 
in air at RT.  The ultimate compressive strength (UCS) was calculated as the peak load 
divided by the pre-test cross-sectional area measured for the specimen.   
 
 80 
3.3.3.3 Fracture toughness testing of capsule-embedded bone cement 
Fracture toughness, K, of capsule-embedded PMMA samples was determined 
using tapered double-cantilever beam (TDCB) specimens as described previously for 
other self-healing systems[65, 85, 89, 178] (Figure 3.1C).  Prior to mechanical testing, a razor 
blade was used to create a pre-crack in the grooved centerline region of the TDCB 
specimen, and specimen was loaded into a Test Resources Q series machine.  The 
specimen was subjected to vertical displacement at 5 µm/s until the peak critical load, Pc, 
was reached and crack propagation was initiated. 
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Figure 3.1: Palacos R PMMA samples for (A) tension, (B) compression, and (C) 
fracture toughness testing. 
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3.4 Results 
3.4.1 Capsule morphology 
Capsules fabricated at an agitation rate of 700 rpm were shown to have 
uniformly spherical morphology with average diameter and shell thickness of 121 ± 24 
µm and 3 ± 0.9 µm, respectively, consistent with measurements obtained previously[171].  
Capsules made at this agitation rate were used for all experiments. 
 
3.4.2 Tensile testing of capsule-embedded bone cement 
Capsule-free (unfilled) Palacos R bone cement used in the current study had a 
UTS of 41.2 ± 1.5 MPa (average ± SEM, n=5) and a Young’s modulus of 1.85 ± 0.04 GPa 
(average ± SEM, n=5), both of which fall within the reported literature range of 25-70 
MPa[11, 90, 107] and 1.36-3.07 GPa[11, 107, 109, 110], respectively.  The UTS of the capsule-
embedded (filled) specimens decreased monotonically with increasing wt% capsules 
(Figure 3.2A), whereas the Young’s modulus of capsule-containing samples appeared to 
drop more sharply up to 5 wt% and then decreased more slowly thereafter (Figure 3.2B).  
The UTS of cements filled with 5 wt% was 29.1± 1.1 MPa (average ± SEM, n=5), which 
lies above the lower limit of the literature-reported values; however, at this capsule 
content, the Young’s modulus for the material (1.13 ± 0.04 GPa, average ± SEM, n=5) was 
outside the range of values reported in the literature.   
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Figure 3.2: Relationship between capsule content and (A) ultimate tensile strength 
and (B) Young’s modulus (average ± SEM, n=5). 
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3.4.3 Compression testing of capsule-embedded bone cement 
Compressive tests of bone cement specimens filled with 5 wt% or fewer capsules 
all exceeded the minimum standard for the compressive strength of 70 MPa[90] (Figure 
3.3A); whereas specimens filled with 10 wt% or higher capsules all had compressive 
strengths that declined steadily below this standard.  Additionally, specimens 
containing 10 wt% or fewer capsules deformed plastically upon failure whereas 
specimens with higher capsule content fragmented upon failure (Figures 3.3B and C). 
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Figure 3.3: (A) Relationship between capsule content and the ultimate compressive 
strength of bone cement (average ± SEM, n=3 with 5 replicates per group).  
Photographs of samples containing (B) 0 wt% and (C) 40 wt% capsules post-
compression testing. 
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3.4.4 Fracture toughness testing of capsule-embedded bone cement 
Figure 3.4A compares the load-vertical displacement curves for unfilled bone 
cement (dashed line) and bone cement filled with 3 wt% capsules (solid line).  The 
unfilled specimen exhibited instantaneous crack growth to complete failure upon 
reaching the peak critical load (~197 N), whereas the specimen filled with 3 wt% 
capsules exhibited slow and progressive crack growth beyond the peak critical load 
(~211 N) prior to the initiation of rapid propagation leading to complete failure. 
Fracture toughness, K, varies based on numerous factors, including the 
molecular weight of the PMMA, sterilization methods, mixing techniques, storage 
conditions, and specimen geometry.  The fracture toughness of unfilled specimens was 
found to be 2.11 ± 0.09 MPa m1/2 and the effects of capsule inclusion on K are shown in 
Figure 3.4B.  The addition of 3 wt% capsules resulted in a modest 13% increase in 
average K while samples filled with 5 wt% and 10 wt% capsules yielded K values 
approximately equal to that of unfilled control samples.  Increasing capsule content to 15 
and 20 wt% resulted in decreases of 26% and 45% in K, respectively when compared 
with unfilled controls, but remained within the literature-reported range of 0.88-2.58 
MPa m1/2 [11, 95-98].     
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Figure 3.4: Load with increasing vertical displacement is shown in (A) for samples 
containing 0 and 3 wt% capsules.  The effect of capsule content on fracture toughness 
is presented in (B) (average ± SEM, n=5).  Fracture plane roughness and sub-surface 
microcracking are observed in SEM images of the side views of TDCB samples 
containing (C) 0 wt% and (D) 3 wt% capsules.  Direction of crack propagation is 
indicated by arrows. 
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SEM images of the crack planes of unfilled (Figure 3.4C) and filled (3 wt%, 
Figure 3.4D) specimens revealed a marked increase in the roughness of the crack plane 
with increasing capsule content.  In capsule-containing specimens, regions of slow, 
progressive crack growth exhibited sub-fracture plane microcracking that was less 
evident in capsule-free control specimens.   
 
3.5 Discussion 
This work describes the static mechanical testing of an acrylic bone cement 
matrix embedded with OCA-containing microcapsules using well-established ASTM 
and ISO mechanical standards for acrylic bone cements.  Each test was designed to 
examine how capsule incorporation affected the integrity of the bone cement relative to 
the unfilled control.  
Overall, composites containing up to 5 wt% capsules had compressive strengths 
above the commercially acceptable minimum and tensile strengths and stiffnesses 
within the reported ranges for commercial acrylic bone cements.    Incorporation of 
higher wt% capsules did however result in mechanical weakening.  Under compression, 
the composite began to fragment at high capsule contents (>25 wt%, Figure 3.3C) and 
could be attributed to the increased void space introduced by the capsules or possibly by 
altering the PMMA powder:MMA monomer ratio that is well-known to influence 
polymerization rate, setting time, and mechanical properties of PMMA[111].  Compression 
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testing of samples with powder:monomer ratios modified to correspond with those in 
filled specimens found the UCS decreased as the ratio became less than 2:1; a 20% 
reduction in UCS with the ratio adjusted to that of samples containing 40 wt% capsules 
(data not shown).  This indicates that while varying the ratio contributes to the observed 
decrease in UCS, it is not the only factor dictating the mechanical property.  The 
decrease in UTS could be attributed to a reduction in the cross-sectional area occupied 
by bone cement matrix in samples containing higher capsule contents or to poor 
shell/matrix interfacial bonding.   
The weakening of a composite matrix through the addition of particulates 
typically occurs when the particulate-matrix interfacial adhesion is poor and increasing 
the particulate content provides a path for crack propagation.  These observations are 
consistent with the general trend of limiting the incorporation of encapsulated healing 
agent to 5-10 wt% in self-healing polymeric composites[178].  Evidence of capsule pull-out 
following tensile tests as well as the fragmenting of the matrix under compression 
observed at high capsule contents suggests poor interfacial bonding between the PUR 
shell material and the PMMA matrix.  In addition to chemical modification of the shell, 
alterations to the physical properties of the capsule, such as changing the shell 
material[168] or adding a coating[167, 179], could be investigated to further promote adhesion 
via increased surface roughness and material interactions.  
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The fracture toughness was relatively unaffected by capsule incorporation up to 
10 wt% capsules, after which it also declined.  For a specimen containing 3 wt% capsules 
(solid line in Figure 3.4A), the load increased linearly with increased displacement 
identically to the unfilled specimen (dashed line in Figure 3.4A) until reaching a load of 
approximately 200 N, after which the crack in the unfilled specimen propagated 
immediately to failure while the crack in the 3 wt% sample advanced in short unstable 
jumps, as reflected by the jagged load-displacement curve.  This difference is also 
reflected in the distinctly different morphologies of the crack planes of the two 
specimens (Figures 3.4C and D).  Previous examinations of self-healing composites 
observed similar stick-slip crack propagation in virgin load-displacement curves[64, 180].   
The addition of 3 wt% OCA-containing capsules only slightly increased the 
fracture toughness when compared with capsule-free bone cement.  In contrast, the 
addition of microencapsulated dicyclopentadiene to an epoxy matrix was previously 
demonstrated to increase fracture toughness up to 127%[178].  As the acrylic bone cement 
is already a highly filled composite of 60-70 wt% PMMA particles in a PMMA matrix, 
the fracture toughness of the bone cement here (2.11 ± 0.09 MPa m1/2) was already nearly 
four times higher than that of neat EPON 828 epoxy[178] (0.55 ± 0.04 MPa m1/2).  
Consequently, the addition of 3 wt% capsules does not appear to have a significant 
toughening effect on the bone cement composite. 
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Finally, it is important to note that the testing described here examines OCA-
containing capsule-filled acrylic bone cement strictly within the context of ASTM and 
ISO commercial standards for the static mechanical properties of acrylic bone cement; 
therefore these results do not speak to the self-healing capacity of the system.  Dynamic 
testing of the self-healing capacity of the system will be presented in a subsequent 
manuscript. 
 
3.6 Conclusions 
The effects of capsule incorporation on the compressive, tensile, and fracture 
toughness properties of bone cement showed that inclusion of greater than 5 wt% 
capsules resulted in the decrease of UCS and UTS below the commercially-required 
levels; the fracture toughness was improved with the incorporation of 3 wt% capsules 
but declined as content was increased above 15 wt%.  These findings suggest that an 
optimal capsule content could be incorporated into PMMA bone cement while 
maintaining its static mechanical properties and support the future promise of this 
system. 
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4. Chapter 4: Functional lifetime of acrylic bone cement 
containing microencapsulated 2-octyl cyanoacrylate 
The manuscript describing the work presented in Chapter 4 is currently in 
preparation and will be submitted for publication shortly. 
 
4.1 Chapter synopsis 
An FDA-approved, water-reactive tissue adhesive, 2-octyl cyanoacrylate (OCA) 
was encapsulated within polyurethane shells and incorporated into Palacos R 
poly(methyl methacrylate) (PMMA) bone cement to assess the bending strength and 
fatigue lifetime of the capsule-embedded materials.  The bending strength, bending 
modulus, and fatigue lifetime of the materials were investigated in accordance with ISO 
standards.  To identify effects specific to encapsulated OCA, PMMA samples without 
capsules and PMMA samples embedded with OCA-containing and OCA-free capsules 
were prepared for bending and fatigue testing.  To investigate capsule susceptibility to 
moisture intrusion, individual capsule compressive strength was examined over 50 d of 
storage in air at room temperature (RT), Ringer’s solution at RT, and Ringer’s solution at 
37 ºC.  The bending strength of OCA-containing specimens was maintained above the 
minimum commercial limit at capsule contents below 5 wt% while the minimum 
bending modulus was exceeded regardless of capsule content.  At low applied cyclic 
loads, the index of fatigue performance of OCA-containing bone cement stored in air at 
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RT was increased 2.5 and 1.8 times when compared to specimens containing OCA-free 
capsules and specimens without capsules, respectively.  However, following 4 weeks of 
storage in Ringer’s solution at 37 ºC, the lifetime extension observed in OCA-containing 
samples was lost.  Studies of individual capsule compressive strength revealed increased 
strength with increasing storage time; storage in Ringer’s solution at 37 ºC produced the 
most rapid increase in individual capsule compressive strength, suggesting the storage 
conditions affected the mechanical properties and on the capsule contents. 
 
4.2 Introduction 
Self-healing materials (SHM) are designed to halt and repair microdamage 
accumulated through repetitive loading.  One of the most broadly reported self-healing 
schemes is that pioneered by White and Sottos et al. in which a polymer matrix is co-
embedded with a catalyst and microcapsules containing a reactive healing agent.  Once 
encountered by a propagating microcrack, the capsule shell is ruptured and releases its 
healing agent into the crack plane where it is exposed to a catalyst embedded in the 
matrix.  In situ curing of the healing agent ensues, halting crack propagation[47, 63-65, 71-73, 
171].  A majority of the systems proposed to date are for civil, mechanical, aerospace, and 
electrical engineering applications.   
Although the SHM field has been steadily growing over the past 10 years, little 
discussion of extension into biomaterials has taken place and current systems do not 
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utilize materials that are acceptable for in vivo applications[47, 171].  Numerous implants 
fail following the accumulation of damage and are potential candidates for the 
introduction of self-healing to biomaterials.  However, as there are stringent 
requirements for materials used in clinical applications, any SHM proposed for a 
biomedical application would need to be assessed from mechanical, biocompatibility, 
and self-healing perspectives.   
Bone cements are two-component materials consisting of a low molecular weight 
poly(methyl methacrylate) (PMMA) powder containing an initiator (e.g. benzoyl 
peroxide), and liquid MMA monomer containing an activator for the initiator.  In situ 
mixing of the liquid and powder initiates polymerization to yield a workable dough that 
is applied to the metallic stem of a TJR implant and cures to form a solid mass after the 
stem is inserted into the bone[8, 171].   PMMA bone cement has a long history of use in 
total joint replacement (TJR) surgeries, does not require post-polymerization 
modifications, and there is significant need for improvement of the material.  Bone 
cement is a brittle material that is weak in tension and strong in compression and is 
susceptible to crack initiation and subsequent propagation resulting from the loading 
patterns experienced in vivo.  For these reasons, the development of a self-healing 
PMMA bone cement is an attractive option for the first self-healing biomaterial designed 
with the aforementioned embedded capsule and catalyst approach[47, 84].   
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As bone cement is considerably weaker than bone[11] and comes with its own set 
of challenges, researchers have proposed composite designs to improve the mechanical 
properties of the material; dispersed particulates and fibers have been investigated to 
increase the toughness, impact strength, and wear resistance of the PMMA by absorbing 
a greater fraction of the load, inhibiting pathways for crack propagation, and resisting 
void formation.  However, in spite of a long history of development in load-bearing 
applications, very few composite devices have progressed to widespread clinical use[47]. 
Previous research by the authors has demonstrated encapsulation of a water-
reactive tissue adhesive, 2-octyl cyanoacrylate (OCA), in polyurethane shells to be 
investigated for applications in a self-healing bone cement[171].  The successful 
incorporation of these capsules into a commercial bone cement matrix was also 
confirmed; tension, compression, and fracture toughness analyses suggested that 5 wt% 
was the maximum capsule content that could be used in the material while still adhering 
to commercial requirements and literature values[181].  Furthermore, the addition of 
OCA-containing capsules to the matrix was not found to affect the viability and 
proliferation of MG63 human osteosarcoma cells treated with extract from these 
materials[181].   
While promising, the previous work examined OCA-containing capsule-filled 
acrylic bone cement strictly within the context of ASTM and ISO commercial standards 
for the static mechanical properties of acrylic bone cement.  Therefore, those results did 
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not speak to the self-healing capacity of the system.  Previous assessments of healing 
efficiency successfully utilized tapered double cantilever beam (TDCB) specimens to 
investigate fracture toughness and healing efficiency[65, 74-76, 87-89].  Typically, the healing 
efficiency of a SHM is determined by testing the “virgin” specimen until a crack 
propagates through the center of the material; the separate pieces are reapposed to allow 
the healing agent to react and bond the surfaces together and the “healed” specimen is 
then tested again.   
Most studies using the TDCB geometry to investigate healing efficiency have 
induced crack propagation through a single, continuously applied load[65, 74-76].  However, 
given that SHM are intended to prevent accumulated damage, their healing efficiency 
under cyclic loading has also been investigated[86-89].  While TDCB tests currently provide 
valuable information about the healing efficiency of some systems, they introduce very 
large defects that are not representative of damage likely to be sustained by a TJR in vivo.  
Also, given the water-reactive nature of the OCA healing agent proposed for this 
application, the time taken to induce crack propagation in the TDCB specimen may 
result in the polymerization of any released OCA by moisture in the air.  A more 
clinically-relevant and informative procedure would involve assessing the healing 
capabilities of a self-healing bone cement system under in vivo conditions to repair 
microdamage.   
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Here we present analyses of the functional lifetime of both individual capsules as 
well as fatigue analyses of capsule-free and capsule-embedded bone cements in air at RT 
and in Ringer’s solution at 37 ºC.  These properties, in addition to the bending strength 
of the material, are investigated to demonstrate the self-healing functionality of this 
OCA/PMMA bone cement SHM system.  Similar to the compressive and tensile 
properties reported previously[181], bending strength decreased with increasing capsule 
content; however, bending modulus was relatively unaffected by capsule inclusion up to 
15 wt%.  At low applied cyclic loads, the index of fatigue performance of OCA-
containing bone cement stored in air at RT was increased 2.5 and 1.8 times when 
compared to specimens containing OCA-free capsules and specimens without capsules, 
respectively.  However, following 4 weeks of storage in Ringer’s solution at 37 ºC, the 
lifetime extension observed in OCA-containing samples was lost.  Studies of individual 
capsule compressive strength revealed increased strength with increasing storage time; 
storage in Ringer’s solution at 37 ºC produced the most rapid increase in individual 
capsule compressive strength, suggesting the storage conditions affected the mechanical 
properties and on the capsule contents.   
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4.3 Experimental section 
4.3.1 Reagents 
Materials were obtained from commercial suppliers and used without further 
purification.  OCA was generously donated by Ethicon, Inc., Raleigh, NC 27616.  Methyl 
ethyl ketone (MEK), methyl isobutyl ketone (MIBK), and cyclohexanone (Sigma Aldrich) 
were used as solvents and 2,4-toluene diisocyanate (TDI) and 1,4-butanediol (1,4-BD) 
(Sigma Aldrich) were used to synthesize the polyurethane prepolymer (pPUR) following 
the protocol outlined by Yang et al. and reported by the authors previously[165, 171].  
Pluronic F-68 (Sigma Aldrich) was used as a surfactant.  Para-toluenesulfonic acid 
(Sigma Aldrich, PTSA) was added to the organic phase as a stabilizer for the OCA 
monomer.  Ringer’s solution was prepared with reagent-grade water (Sigma), sodium 
chloride, potassium chloride, and calcium chloride (Sigma Aldrich).  Commercially-
available Palacos R PMMA bone cement (Zimmer) was used for all experiments 
reported herein. 
 
4.3.2 Microcapsule preparation 
Microcapsules were prepared and characterized as described previously[171].  
Briefly, at room temperature, Pluronic F-68 surfactant (1.84 g) was dissolved in 
deionized water (90 mL) in a 250 mL beaker.  The solution was agitated for 1 h with a 
digital mixer (VWR PowerMax Elite Dual-Speed Mixer) before beginning the 
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encapsulation procedure.  The aqueous phase was suspended in a hot water bath and 
heated to 50 ºC prior to the addition of the organic phase and chain extender. 
OCA (4 mL) was dissolved in MIBK (8 mL) and pPUR (3 g) was dissolved in 
MEK (10 mL) separately at room temperature.  PTSA (1%) was added to the OCA-MIBK 
solution to further stabilize the OCA monomer.  The pPUR- and OCA-containing 
solutions were then added simultaneously to the aqueous phase but not mixed prior to 
this addition.  After the organic and aqueous phases were combined, the 1,4-BD (3 mL) 
chain extender was added dropwise to the stirring mixture via a syringe to form the 
segmented PUR shell material consisting of hard TDI-based segments and soft 1,4-BD 
segments.  After a reaction time of 2 h at an agitation rate of 700 rpm, the mixer was 
switched off and the suspension of microcapsules rinsed with deionized water and 
vacuum filtered.  Capsules were air-dried prior to use in the following experiments[171].  
To manufacture OCA-free control capsules, the OCA was replaced with additional 
MIBK (4 mL) and the agitation rate reduced to 450 rpm; all other aspects of the 
encapsulation procedure were performed identically.   
 
4.3.3 Preparation of capsule-containing bone cement samples 
The powder component was mixed with the liquid component according to the 
manufacturer’s instructions[177], OCA-containing capsules were added to the slurry, and 
the resultant material was added to molds to form the desired specimen shape.  Samples 
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were cured in the molds for at least 1 h, released, and smoothed with 240 mesh silicon 
carbide to conform to the specified geometrical requirements.  The wt% of OCA-
containing capsules in the bone cement composites ranged from 0-40 wt% where the 
wt% of total particulates (OCA capsules plus PMMA powder) was held constant at 67 
wt% in all specimens. 
 
4.3.3.1 Bending testing of capsule-embedded bone cement 
Following ISO 5833, rectangular bone cement samples were cured in silicone 
rubber molds for 1 h and then smoothed, producing specimens with dimensions of 10 ± 
0.1 mm by 3.3 ± 0.1 mm by 75 ± 0.1 mm.  24 h post-manufacturing, specimens were 
subjected to 4-point bending at a crosshead speed of 5 ± 1 mm/min until failure using a 
Test Resources 840LE2 Electrodynamic tension-compression-flexural fatigue machine.  
All tests were performed in air at RT.  The bending strength, B, was calculated using 
Equation 1: 
    
   
   
                                                                                    
 
where F is the force at break (in N), b is the average measured width of the specimen (10 
mm), h is the average measured thickness (3.3 mm), and a is the distance between the 
inner and outer loading points (20 mm).  
Equation 2 was used to determine the bending modulus, E: 
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where f is the difference in the deflection under the loads of 15 and 30 N (in mm), 
b is the average measured width of the sample (10 mm), h is the average thickness (3.3 
mm), l is the distance between the outer loading points (60 mm), ΔF is the load range 
over which the deflection was measured (15 N), and a is the distance between the inner 
and outer loading points (20 mm).  The commercial requirements for B and E as 
described in ISO 5833 are 50 and 1800 MPa, respectively.    
 
4.3.3.2 Fatigue testing of capsule-embedded bone cement 
Specimens were prepared as described for bending testing.  Samples were either 
tested 1 d after manufacturing or after 4 weeks of storage in Ringer’s solution at 37 ºC[99, 
100].  The samples were cycled to failure under load control using a Test Resources 
840LE2 Electrodynamic tension-compression-flexural fatigue machine.  The bending 
strength of capsule-free samples was used as the reference strength; during fatigue 
analyses, various upper stress levels ranging from 50-90% of the reference value were 
selected for testing and 10 samples were cyclically-loaded to each of these maximum 
stress levels[106].  A loading ratio R, σmin/σmax, of 0.05 and a frequency of 5 Hz were used to 
mimic normal gait[34, 99, 100, 105].   
Just as capsule-free control samples were tested to certain percentages of their 
reference strength, specimens containing encapsulated OCA were cyclically-loaded at 
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maximum stress levels that were 50-90% of their reference strength using R=0.05 and a 
frequency of 5 Hz.  Based on previous studies of the static mechanical properties of 
capsule-containing PMMA samples[181], specimens containing 5 wt% capsules were used 
for all fatigue experiments of capsule-embedded samples.  To determine if an 
encapsulated OCA system went beyond passive toughening to actively slow and repair 
damage, samples containing 5 wt% of OCA-free capsules were tested under the same 
conditions.   
The probability-of-failure, P(Nf), was obtained using the equation P(Nf) = (M-
0.3)/(G+0.4), where M and G are the failure order number and the total number of 
specimens tested, respectively[105, 182].  The failure order number is defined as the number 
assigned to an Nf value to denote its position within a list of G values arranged in 
ascending order of magnitude; M=1,2,3…G.  For a given stress level, the Nf results were 
fitted to the linearized form of the 3-parameter Weibull equation, as shown in Equation 
3: 
 
                             
 
    (  ) 
     (     )                                                
 
where N0 is the minimum or guaranteed fatigue life, Na is the characteristic fatigue life, 
and b is the Weibull slope.  N0 was determined from the vertical asymptote of the plot of 
ln(Nf) versus ln ln[1/(1-P(Nf))][43, 105, 183]; this is the number of cycles below which all 
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specimens have a 100% probability of survival.  The Weibull slope, b, is a measure of the 
spread of the data, and Na, the characteristic fatigue life, is the number of cycles below 
which lie 63.2% of the Nf results.  Both of these parameters are determined from the 
linear fit of the plot of ln(Nf-N0) versus ln ln[1/(1-P(Nf))][43, 105, 183].  The Weibull mean, 
NWM, also called the index of fatigue performance, was calculated as shown in Equation 
4: 
                                                                               √                                                                   (4) 
 
4.3.4 Capsule susceptibility to moisture intrusion 
OCA-containing capsules were stored in glass scintillation vials in air at RT for 
50 days or soaked in Ringer’s solution at RT or 37 ºC for the same duration.  Small 
samples of capsules were removed from each vial at various time points, dried, and 
subjected to compression testing using a dynamic mechanical analyzer (TA Instruments 
RSA-G2 solid analyzer, DMA) as described previously[171].  Displacement of the upper 
DMA plate was applied at 5 µm/s until shell compressive failure was observed.  Capsule 
compressive strength was determined by dividing the maximum compressive load by 
the pre-test equatorial cross-sectional area measured for each capsule.  A vacuum 
sputter coater (Denton Desk IV) was used to deposit a 10 nm layer of gold onto post-
compression samples for scanning electron microscope (FEI XL30 SEM-FEG, SEM) 
imaging to examine capsule morphology with increasing storage time. 
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4.3.5 Statistical analyses 
Independent two-sample t-tests were used to compare the average individual 
capsule compressive strength of samples taken from each treatment at a given time 
point.  The level of statistical significance was set at p < 0.05.   
 
4.4 Results 
4.4.1 Capsule morphology 
Capsules fabricated at an agitation rate of 700 rpm were shown to have uniform 
spherical morphology with average diameter and shell thickness of 132 ± 29 µm and 2 ± 
0.8 µm, respectively, consistent with measurements obtained previously[171, 181].  Capsules 
made at this agitation rate were used for all experiments with OCA-containing 
specimens.  OCA-free capsules made at 450 rpm were also shown to have spherical 
morphology with average diameter and shell thickness of 89 ± 15 µm and 3 ± 0.7 µm, 
respectively, resembling those containing OCA. 
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4.4.2 Bending testing of capsule-embedded bone cement 
Capsule-free Palacos R bone cement used in the current study had a bending 
strength (B) of 74.9 ± 1.2 MPa (average ± SEM, n=5) and a bending modulus (E) of 3047 ± 
56 MPa (average ± SEM, n=5); these values are well above those of 50 MPa and 1800 MPa 
required for B and E of commercial bone cements and are similar to those reported in 
the literature for Palacos R[90, 99].  B decreased monotonically with increasing OCA-
containing capsule content; however, E remained fairly constant regardless of capsule 
content (Figures 4.1A and 4.1B).  The average bending strengths of samples containing 
fewer than 5 wt% capsules lie above the commercial minimum and the bending 
modulus requirement was met at all capsule contents tested.  Similar results were found 
when testing samples containing OCA-free capsules; B was maintained at all contents 
lower than 10 wt% while E always exceeded the commercial minimum. 
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Figure 4.1:  Relationship between capsule content and (A) bending strength and (B) 
bending modulus (average ± SEM, n=5) for specimens embedded with OCA-
containing and OCA-free capsules. 
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4.4.3 Fatigue testing of capsule-embedded bone cement 
The reference bending strengths and fatigue lives of the various specimen types 
are summarized in Figure 4.2A.  The reference strengths, as determined by bending 
testing to failure, were 74.9 ± 1.2, 63.7 ± 2.2, and 44.2 ± 1.5 MPa for capsule-free 
specimens and those embedded with 5 wt% OCA-free capsules and 5 wt% OCA-
containing samples, respectively (Figure 4.2A).  Fatigue testing 1 d post-manufacturing 
at maximum cyclic stress levels of 50, 70, 80, and 90% of the reference stress was 
performed to generate the S-N relationships presented in Figure 4.2B. 
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Figure 4.2: The reference bending strengths for each sample type are depicted in (A) 
(n=10).  The fatigue test results as applied stress versus the number of cycles to failure 
for samples tested after 1 d storage in air are summarized in (B). 
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Fatigue life was increased with decreasing upper cycling load regardless of 
specimen type; however, differences between the reference bending strengths 
complicated the comparisons across sample type (Figure 4.2B).   Although the reference 
strength of OCA-containing samples was lower than those of the other specimen types, 
the samples underwent more cycles prior to failure at lower load levels.  Extrapolation 
of the S-N data suggested that at upper cycling loads less than 40 N (~22 MPa), OCA-
containing specimens would outperform the others, regardless of reference strength.  
Samples of each type were cyclically loaded at a maximum force of 40 N at a frequency 
of 5 Hz with R=0.05; the results of fatigue testing at this lower load condition are 
presented in Figure 4.3.  
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Figure 4.3: Number of cycles to failure in samples tested to a maximum load of 40 N 
(n=10).  OCA-containing specimens underwent approximately two times as many 
cycles prior to failure at this lower load level. 
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The numbers of cycles to failure were found to be significantly increased in 
samples containing OCA-filled capsules when tested to 40 N when compared with 
capsule-free controls and samples containing 5 wt% capsules without OCA.  Table 4.1 
summarizes the properties of the fatigue samples tested to upper cycling loads of 40 N 
in air. 
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Table 4.1: Mechanical properties of capsule-filled and capsule-free bone cements 
tested in air  
Condition Capsule free Capsules with OCA Capsules without OCA 
B (MPa) 74.9 ± 1.2 44.2 ± 1.5 63.7 ± 2.2 
E (MPa) 3047 ± 56 3078 ± 14 2902 ± 41 
Characteristic 
fatigue life, Na 
(cycles) 
410658 532698 284916 
Minimum fatigue 
life, N0 (cycles) 
64786 84966 134427 
Weibull slope, b 0.5685 0.6025 0.5848 
Weibull mean, NWM 309632 544661 217882 
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Following 4 weeks of storage in Ringer’s solution at 37 ºC, the B of unfilled bone 
cement was relatively unchanged, increasing slightly, but not significantly, to 75.3 ± 1.4 
MPa; the B of samples filled with 5 wt% OCA-containing capsules increased to 51.6 ± 1.6 
MPa while B of specimens containing OCA-free capsules decreased slightly to 60.5 ± 0.5 
MPa (Figure 4.4A).  Over the same period, the average E of unfilled bone cement 
decreased from 3047 ± 56 MPa to 2806 ± 36 MPa while the E of samples filled with 5 wt% 
OCA-containing capsules decreased from 3078 ± 14 MPa to 2689 ± 38 MPa and E of 
samples filled with 5 wt% OCA-free capsules decreased from 2902 ± 41 MPa to 2566 ± 26 
MPa.  However, all average values for E are substantially higher than the 1800 MPa 
minimum commercial limit regardless of storage condition. 
Fatigue testing was conducted at stress levels 50, 70, 80, and 90% of the specimen 
reference strengths to generate the S-N relationships shown in Figure 4.4B.  As observed 
in samples tested in air 1 d after fabrication, fatigue lifetime was extended as the 
maximum applied stresses decreased.  While the average number of cycles to failure was 
found to be slightly increased in capsule-free samples when compared to their 
counterparts that were not stored in Ringer’s solution (Figures 4.2B and 4.4B), the 
number of cycles to failure was reduced following storage in Ringer’s solution in 
specimens containing either type of capsules (Figures 4.2B and 4.4B).  Extrapolation of 
the S-N data revealed that there was no load level at which OCA-containing specimens 
would outperform the others.   
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Figure 4.4: The reference bending strengths for each sample type are depicted in (A) 
(n=10).  The fatigue test results as applied stress versus the number of cycles to failure 
for samples tested after 4 weeks storage in Ringer’s solution at 37 ºC are summarized 
in (B). 
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4.4.4 Capsule susceptibility to moisture intrusion 
Figure 4.5 summarizes the effects of storage time on the compressive strength of 
individual capsules stored in air at RT and in Ringer’s solution at RT and 37 ºC over a 
period of 50 days.  In all cases, capsule compressive strength increased with days in 
storage; the rate of strengthening was most rapid for capsules stored at 37 ºC in Ringer’s 
solution, followed by Ringer’s solution at RT, and then in air at RT.  Capsules reached 
apparent upper limits of ~16-17 MPa for capsules stored in Ringer’s solution at 37 ºC, 
and ~14 MPa for capsules stored at RT in either air or Ringer’s solution.  The average 
individual capsule compressive strengths for capsule stored in each condition were only 
significantly different at days 5 and 15 between capsules stored at RT and those in 
Ringer’s solution at 37 ºC 
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Figure 4.5: Compressive strength of individual capsules over storage time.  Capsules 
were stored in air at RT and Ringer’s solution at RT or 37 ºC (average ± SEM, n=3 with 
3 replicates per group).  Asterisks indicate significance between the RT and Ringer’s 
37 ºC samples. 
 
 118 
SEM images of capsules fractured after 15 days of storage time clearly showed 
increased capsule shell thickness in the sample stored at 37 ºC in Ringer’s solution 
(Figure 4.6A) when compared to the specimen stored in air at RT (Figure 4.6B). 
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Figure 4.6: SEM images of capsule morphology with exposure to (A) Ringer’s solution 
at 37 ºC and (B) air at RT for 15 days of storage time.  Note the increased shell 
thickness of the capsule stored in Ringer’s solution when compared with the capsule 
stored in air. 
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4.5 Discussion  
One of the primary challenges associated with the development of SHMs is 
identifying a proper balance between decreasing the mechanical strength of the material 
while increasing its self-healing capacity; this was observed here as the addition of 
capsules gradually decreased the static bending strength of the PMMA.  For OCA-
containing specimens, the required bending strength B was maintained at capsule 
contents of less than 5 wt%; this was expected as 5 wt% was also the maximum limit for 
compression and tension properties[181] and bending is a combination of these two forces.  
In specimens embedded with OCA-free capsules, B was maintained at capsule contents 
of less than 10 wt%; this difference in maximum allowable wt% of capsules is attributed 
to the slightly decreased size of the OCA-free capsules when compared to the OCA-
containing capsules.   The bending specimens were all smoothed prior to testing, but any 
surface defects serve as initiation sites for crack propagation.  Capsules at or near the 
surface of the material could act as initiation sites and contribute to the decrease in 
bending strength observed in samples containing either type of capsule; with increasing 
capsule content, the number of defects at or near the surface increased, resulting in more 
initiation sites and subsequently a decreased B.  Even though the bending strength of the 
PMMA is decreased through capsule inclusion (Figure 4.1A), these strengths are still 
much higher than the physiologically-relevant values at which the material will 
ultimately be used. 
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Interestingly, the bending modulus E remained remarkably consistent regardless 
of capsule content in samples embedded with OCA-containing and OCA-free capsules.  
Based on Equation 2, the deflection f is the only variable that could change between the 
sample types and/or with increasing capsule content; consistent f regardless of 
increasing capsule wt% suggests that while increasing capsule content increased the 
crack initiation, crack propagation rates were unchanged.  Crack propagation rates in 
OCA-free capsules may be influenced by the size of the capsules as well as differences in 
the mechanical properties of the individual capsules, leading to the slightly lower E 
observed in samples with OCA-free capsules (Figure 4.1B).   
Higher cycling stresses resulted in a decreased number of cycles prior to failure 
regardless of sample type or reference bending strength (Figure 4.2).  Differences 
between the reference strengths make comparisons difficult across sample type; 
however, at lower applied cyclic stresses, specimens containing encapsulated OCA 
underwent more cycles prior to failure than the other sample types (Figure 4.3).  For the 
system’s intended application, behavior at lower stress levels is more indicative of the in 
vivo environment; a SHM of this design is not intended to repair damage that occurs 
near the upper limits of the PMMA’s mechanical properties. 
The addition of particulates to PMMA has previously been found to retard 
fatigue failure through increasing the fracture toughness, impact strength, and wear 
resistance of the material by absorbing a greater fraction of the load, inhibiting pathways 
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for crack propagation, and resisting void formation.  The fatigue life in samples 
containing OCA-free capsules and no capsules were approximately equal at the lowest 
load level tested (Figure 4.3); as it was hypothesized that additives would contribute to 
lifetime extension, these findings support previous data suggesting the need for 
improvement in the interfacial bonding between the capsule shell and PMMA matrix[181]. 
From this fatigue data, it can be inferred that other factors are contributing to the 
increased number of cycles to failure observed in OCA-containing samples. 
Brown et al. reported that when healing agent was released into the crack plane 
of a cyclically-loaded TDCB specimen, it polymerized to form a polymer wedge, 
generating a crack tip shielding mechanism[87, 88].  This shielding wedge resulted in 
temporary crack arrest and extended the fatigue lifetime by 20 times.  Hydrodynamic 
pressure crack-tip shielding due to viscous flow has also been found to retard crack 
growth[87], indicating that the initiation of healing agent polymerization could act to slow 
crack growth before full polymerization and subsequent polymer wedge formation.  The 
forces required to squeeze a viscous fluid from the crack plane during unloading 
provided crack-tip shielding.  Testing with TDCB specimens introduces macrocracks far 
larger than those intended to be repaired by these SHMs in their usage environments, 
but it is hypothesized that similar mechanisms are contributing to the increased fatigue 
lifetime observed in PMMA samples containing encapsulated OCA.   
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Analyses using the linearized 3-parameter Weibull model indicated that both the 
characteristic life (Na) and guaranteed fatigue life (N0) were increased in OCA-containing 
specimens when compared to the other specimen types (Table 4.1).  The Weibull slope is 
an indicator of the likelihood of specimen failure; distributions with higher slopes 
indicate samples that are approaching failure.  Additionally, the slope describes the 
variability or degree or scatter in the cycles to failure data[183]; an increased slope 
indicates a reduction in scatter, meaning that the samples fail at more consistent cycle 
numbers.  A decrease in the Weibull slope, as seen with the lower stress levels tested 
here, indicates a broader range of Nf; this is to be expected when the PMMA is tested at 
lower stresses and the crack propagation behavior dominates over the crack initiation 
behavior[30].  The Weibull mean (NWM), or index of fatigue performance, describes the 
overall fatigue performance as a function of both the magnitude of the fatigue life and 
the variability of the cycles to failure[184]; specimens containing encapsulated OCA had a 
Weibull mean that was more than double those of specimens without capsules and with 
OCA-free capsules (Table 4.1).    
Given the multitude of variables involved with fatigue testing, such as the 
sample preparation methods and geometry, the testing procedure, the storage and 
testing conditions, etc. it is difficult to make meaningful cross-study comparisons to 
determine how capsules specifically improve fracture toughness and fatigue lifetime of 
bone cement when compared with other additives.  Furthermore, to our knowledge, no 
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previous studies investigating how the incorporation of encapsulated materials into 
bone cement affects fatigue life have been undertaken.  However, this work represents a 
new avenue of PMMA research and confirms the potential of a self-healing biomaterial 
based on PMMA and OCA. 
For more physiologically-relevant information, PMMA specimens were stored in 
Ringer’s solution for 4 weeks to allow for 95% saturation of the material to mimic the 
behavior of the material in vivo[99, 100].  Capsule-free samples soaked in Ringer’s displayed 
moderately increased lifetimes over their counterparts stored in air at RT (Figures 4.2B 
and 4.4B); this is supported by numerous studies investigating the effects of storage 
conditions on the properties of bone cement[90, 185].  Other researchers have previously 
reported extended fatigue life in samples soaked in saline during testing at room 
temperature[185] which was attributed to the plasticizing effect of the saline at the crack 
tip[185, 186].   
Capsule-containing samples displayed reduced fatigue lifetime following storage 
in Ringer’s at 37 ºC when compared with their counterparts stored in air at RT.  While 
the fatigue life of OCA-free samples was reduced only slightly after storage, OCA-
containing specimens displayed a marked reduction in fatigue life following storage in 
Ringer’s solution for 4 weeks (Figures 4.2B and 4.4B).  The slight reduction in fatigue life 
in OCA-free specimens is attributed to the infiltration of Ringer’s solution between the 
capsule and PMMA matrix, further reducing adhesion between the two and 
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encouraging propagation around rather than through the capsule.   Testing with OCA-
containing specimens suggests that the encapsulated OCA gradually polymerizes over 
storage time in Ringer’s solution at 37 ºC, thus reducing its healing capacity and 
resulting in a material with similar fatigue characteristics as one containing OCA-free 
capsules.   
Investigation of the effects of storage conditions on capsule compressive strength 
reveal clear trends suggesting capsule strength was increased following exposure to 
physiological conditions; it is hypothesized that polymerization of the core OCA 
material resulting from water infiltration increased capsule shell thickness (Figure 4.6).  
Significant differences in compressive strength were only observed between capsules 
stored at RT and in Ringer’s 37 ºC after 5 and 15 d of storage, suggesting that the 
capsules are most susceptible to moisture right after fabrication.  The strengthening of 
capsules exposed only to moisture from the surrounding air also indicates that capsule 
hermeticity must be improved for this system’s functionality to be maintained for 
periods of time prior to material implantation.     
These results in combination with the fatigue studies on post-Ringer’s specimens 
indicate the need to further shield the core material to extend the reactive lifetime of the 
encapsulated OCA.  Individual capsules stored in air at RT reached maximum strength 
after 50 days of storage and exhibited increased compressive strength following only 15 
d of storage time, suggesting the shelf life of the capsules could be improved.  While the 
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rate of moisture infiltration may have been altered somewhat by the presence of the 
PMMA matrix, various capsule modifications could minimize water infiltration and 
extend capsule shelf life.  Increasing the hydrophobicity of the shell material may be a 
promising approach to reducing water infiltration and extending the reactive lifetime of 
the OCA.  Ongoing work is focused on modifying the PUR soft segments to increase 
shell hydrophobicity.  Improvements to capsule/matrix adhesion could simultaneously 
increase the maximum allowable wt% of capsules to increase fatigue lifetime while 
reducing moisture infiltration to extend the functionality of the encapsulated agent. 
In addition to maximizing adhesion at the shell/PMMA interface while 
minimizing water infiltration, visualization of healing agent release in the crack plane 
would enable better understanding healing agent release in response to fatigue damage.  
Encapsulation of dyed OCA is currently in progress to be used for this application.  
Given the modes of bone cement failure in vivo, more complex loading strategies should 
be employed to investigate the ability of this system to minimize crack initiation at the 
cement/bone and cement/stem interfaces, the response of the material following variable 
amplitude loading, as well as a reduction in wear debris generation.  
 
4.6 Conclusions 
Capsule inclusion above 5 wt% resulted in the decrease of B below the 
commercially-required levels while E was maintained at all capsule contents tested.  
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OCA-containing bone cement displayed superior fatigue properties at physiologically-
relevant load levels when compared with control specimens and those containing OCA-
free capsules.  However, following storage of PMMA samples in Ringer’s solution at 37 
ºC for 4 weeks, the reparative function of encapsulated OCA was diminished.  
Individual capsules demonstrated susceptibility to moisture intrusion, as indicated by 
increasing capsule compressive strength resulting from increased shell thickness after 50 
d of storage under various conditions.  These results support the need to investigate 
methods of reducing permeability of the capsule shell but also support the future 
promise of a self-healing bone cement based on OCA and PMMA. 
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5. Chapter 5: Cytotoxicity testing of acrylic bone cement 
embedded with microencapsulated 2-octyl 
cyanoacrylate 
Portions of the text and figures included in Chapter 5 were recently accepted for 
publication in the Journal of Biomedical Materials Research Part B: Applied 
Biomaterials.  The full citation for the article is: Brochu Alice BW, Evans GA, Reichert 
WM. 2013. Mechanical and cytotoxicity testing of acrylic bone cement embedded with 
microencapsulated 2-octyl cyanoacrylate. J Biomed Mater Res Part B 2013.  This article 
does not yet have a publication date; however, John Wiley & Sons Ltd. does not require 
permission for authors to reuse their own articles, but an optional grant of license will be 
obtained as soon as one is available.  Please note that this manuscript described the work 
for Specific Aims 2 and 4 and was in to two chapters for this dissertation to maintain 
parallel structure with the Specific Aims. 
 
5.1 Chapter synopsis 
2-octyl cyanoacrylate (OCA), an FDA-approved, water-reactive tissue adhesive, 
was microencapsulated in polyurethane shells and incorporated into Palacos R bone 
cement.  Extracts from Palacos R bone cement, capsule-embedded Palacos R bone 
cement, and OCA were prepared in complete culture medium.  Viability and 
proliferation of MG63 human osteosarcoma cells cultured with these extracts were 
investigated over 24-72 h; viability was determined with live/dead staining and 
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proliferation was assessed using EdU staining.  The effects on cell proliferation and 
viability in response to extracts prepared from capsule-embedded and commercial bone 
cements were not significantly different from each other, whereas extracts from OCA 
were moderately toxic to cells.   
 
5.2 Introduction 
Poly(methyl methacrylate) (PMMA) bone cement is commonly used to anchor 
the metallic stem of a total joint replacement to native bone and serves to uniformly 
transfer the body weight from the implant to the tissue.  Bone cements are generally 
two-component materials consisting of a low molecular weight PMMA powder 
containing an initiator (e.g. benzoyl peroxide), and liquid MMA monomer containing an 
activator for the initiator.  In situ mixing these materials initiates polymerization to yield 
a workable dough that is applied to the implant and cures to form a solid mass after the 
stem is inserted to provide stability to the implant in vivo[8, 171].  
In addition to the comprehensive testing procedures required to determine the 
mechanical properties of bone cement, these materials are also subject to cytotoxicity 
and tissue compatibility standards.  Primary toxicity concerns associated with PMMA-
based bone cements include localized cell death due to the exothermic reaction of the 
MMA and leaching of residual monomer from the matrix[113].  An estimated 3-5% of the 
MMA remains 15 minutes post-polymerization and is reduced to about 1-2% over time 
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as the residues are eliminated through the bloodstream[114, 115].  N,N-dimethyl-p-toluidine, 
which is present in small amounts (≤ 2% of the liquid component) and initiates MMA 
polymerization when it reacts with benzoyl peroxide present in the powder component, 
is very toxic at low concentrations and is able to inhibit protein synthesis and cause 
chromosomal mutations[114].  
Previous groups have investigated strategies to reduce the toxicity of bone 
cement; these primarily include the use of other monomers, such as ethyl 
hexylacrylate[113, 187, 188], 2-ethylhexyl methacrylate, and trimethylolpropane 
trimethacrylate[189], to reduce the toxicity of any residual monomer and/or decrease the 
curing temperature to minimize cytotoxicity and heat-induced tissue necrosis.  Use of 
these materials have also been proposed to improve bone cement’s bioactivity and 
mechanical strength[187, 188]. 
The current study presents the first characterization of the cytotoxicity of a 
biomaterial formulation consisting of OCA-containing microcapsules embedded in 
commercial PMMA bone cement.  Extracts from Palacos R bone cement, capsule-
embedded Palacos R bone cement, and OCA were prepared in complete culture 
medium.  Those prepared from the capsule-embedded and commercial bone cements 
had little effect on cell proliferation and viability and were not significantly different 
from each other, whereas extracts prepared from OCA alone were moderately toxic to 
cells.  Overall the addition of 10 wt% of OCA-containing microcapsules to the 
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commercial bone cement was found to have in insignificant effect on the toxicity of the 
material. 
 
5.3 Experimental section 
5.3.1 Reagents 
Unless otherwise specified, materials were obtained from commercial suppliers 
and used without further purification.  OCA was generously donated by Ethicon, Inc., 
Raleigh, NC 27616.  Methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), and 
cyclohexanone (Sigma Aldrich) were used as solvents and 2,4-toluene diisocyanate (TDI) 
and 1,4-butanediol (1,4-BD) (Sigma Aldrich) were used to synthesize the polyurethane 
prepolymer (pPUR) following the protocol outlined by Yang et al. and reported by the 
authors previously[165, 171].  Pluronic F-68 (Sigma Aldrich) was used as a surfactant.  Para-
toluenesulfonic acid (Sigma Aldrich, PTSA) was added to the organic phase as a 
stabilizer for the OCA monomer.  Commercially-available Palacos R PMMA bone 
cement (Zimmer) was used for all experiments reported herein.  Loctite® Super Glue 
and copper sheets were also purchased and used as received. 
Minimum Essential Medium Eagle (Sigma), heat-inactivated fetal bovine serum, 
sodium pyruvate, non-essential amino acids, and penicillin-streptomycin (Gibco) were 
used for cell culture.  Calcein AM, Hoechst 33342, Click-iT EdU Alexa Fluor 488 kit 
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(Invitrogen), and Dulbecco’s Phosphate Buffered Saline (Gibco, DPBS) were used in cell 
staining procedures. 
 
5.3.2 Microcapsule preparation 
Microcapsules were prepared and characterized as described previously[171].  
Briefly, at room temperature, Pluronic F-68 surfactant (1.84 g) was dissolved in 
deionized water (90 mL) in a 250 mL beaker.  The solution was agitated for 1 h with a 
digital mixer (VWR PowerMax Elite Dual-Speed Mixer) before beginning the 
encapsulation procedure.  The aqueous phase was suspended in a hot water bath and 
heated to 50 ºC prior to the addition of the organic phase and chain extender. 
OCA (4 mL) was dissolved in MIBK (8 mL) and pPUR (3 g) was dissolved in 
MEK (10 mL) separately at room temperature.  PTSA (1%) was added to the OCA-MIBK 
solution to further stabilize the OCA monomer.  The pPUR- and OCA-containing 
solutions were then added simultaneously to the aqueous phase but not mixed prior to 
this addition.  After the organic and aqueous phases were combined, the 1,4-BD (3 mL) 
chain extender was added dropwise to the stirring mixture via a syringe to form the 
segmented PUR shell material consisting of hard TDI-based segments and soft 1,4-BD 
segments.  After a reaction time of 2 h at an agitation rate of 700 rpm, the mixer was 
switched off and the suspension of microcapsules rinsed with deionized water and 
vacuum filtered.  Capsules were air-dried prior to use in the following experiments[171]. 
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5.3.3 Biocompatibility of capsule-containing bone cement 
5.3.3.1 Preparation of bone cement and OCA extracts 
The powder component was mixed with the liquid component according to the 
manufacturer’s instructions[177], OCA-containing capsules were added to the slurry, and 
the resultant material was added to rectangular silicone rubber molds to form the 
desired extraction specimens (Figure 5.1A).  Samples containing 0 or 10 wt% OCA-
containing capsules were prepared; the total particulates (OCA-containing capsules plus 
PMMA powder) in the composites were held constant at 67 wt%.  Samples were cured 
in the molds for 1 h, released, cured at RT for an additional 23 h and then autoclaved at 
120 ºC for 30 minutes.  Each sample was then immersed in a 50 mL conical tube 
containing sterile complete culture medium and incubated for 24 h at 37 ºC[113] (Figure 
5.1B).  A ratio of 0.2 g bone cement to 1 mL extract medium was maintained[190].   
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Figure 5.1: (A) Rectangular specimens were prepared and (B) extracted into complete 
culture medium in a 50 mL conical tube. 
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To prepare OCA extracts, 15 µL OCA was added to 5 mL culture medium and 
incubated at 37 ºC for 24 h in a 15 mL conical tube[191, 192]; the OCA polymerized 
immediately upon contact with the culture medium.  As the OCA was not received 
sterile, the media was then filtered prior to use in these experiments.  Loctite® Super 
Glue (ethyl cyanoacrylate) and copper sheets[113] were selected as liquid and solid 
positive controls for these studies.  To prepare the Super Glue extracts, 15 µL of Super 
Glue was added to 5 mL culture medium and incubated at 37 ºC for 24 h in a 15 mL 
conical tube; the Super Glue polymerized immediately upon contact with the culture 
medium.  Copper samples were immersed in a 15 mL conical tube and incubated at 37 
ºC for 72 h; a ratio of 0.2 g copper to 1 mL extract medium was maintained[190].  Extracts 
from the Super Glue and copper were both filtered prior to addition to cells. 
 
5.3.3.2 Cell viability and proliferation 
MG63 human osteosarcoma cells have been used in numerous biocompatibility 
studies[113, 114, 117-120] because they share several features with normal human osteoblasts, 
including secretion of insulin-like growth factor, binding proteins, matrix 
metalloproteinases, and osteocalcin.  Similar to undifferentiated osteoblasts, MG63 cells 
also synthesize collagen types I and III and have a low basal expression of alkaline 
phosphatase that is increased in response to 1,25-dihydroxyvitamin D3[120, 193]. 
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MG63 human osteosarcoma cells were cultured in Minimum Essential Medium 
Eagle supplemented with 10% heat-inactivated fetal bovine serum, and 1% each of 
sodium pyruvate (100 mM), non-essential amino acids (100x), and penicillin-
streptomycin (10,000 units/mL penicillin and 10,000 µg/mL streptomycin).  The cells 
were routinely passaged and incubated at 37 ºC in a humidified environment of 5% CO2 
in air.  
Cells were passaged and plated in 96-well plates at a density of 2000 cells/well 
and allowed to attach for 24 h.  After 24 h, the growth media was replaced by the same 
volume of treatment media.  Media was also changed in the control wells so that cells in 
all wells were exposed to a media change 24 h after plating.  For all experiments, cells in 
3 different wells received each treatment and the experiments were performed 4 times 
with new extract media prepared from different material samples for each trial.   
To investigate the effects of bone cement extract, four treatment groups were 
studied: an undiluted extract from capsule-free PMMA; undiluted extract from capsule-
embedded PMMA (10 wt% capsules ); and extract from capsule-embedded PMMA (10 
wt% capsules) diluted to 50 and 25% using fresh media[113].  To investigate the effects of 
OCA extract, three treatment groups were studied: OCA extract diluted to 50, 25, and 
10% using fresh media[191].  A negative control of cells not treated with any material 
extract and positive controls of cells treated with extract prepared from Loctite® Super 
Glue and copper sheets were also investigated. 
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Cell viability was assessed by a combination of staining with calcein AM and 
Hoechst 33342.  After 72 h culture, the various treatment media were removed and cells 
rinsed twice with DPBS containing calcium chloride and magnesium chloride (1X), then 
incubated at 37 ºC in calcein AM in DPBS (0.75 µL/1.5 mL) for 20 minutes.  The DPBS 
containing calcein AM was removed and the cells were rinsed twice with DPBS and 
incubated an additional 20 min at 37 ºC in DPBS containing Hoechst 33342 (1.5 µL/1.5 
mL).  The DPBS containing Hoechst 33342 was removed and the cells were rinsed twice 
with DPBS, and then imaged using a Nikon Eclipse TE2000-U inverted fluorescence 
microscope and NIS Elements software (Nikon).   Images were analyzed with ImageJ. 
Cell proliferation was investigated with EdU staining following the 
manufacturer’s instructions included with the Click-iT EdU Alexa Fluor 488 kit.  The 
stain was performed following 24, 48, and 72 h of culture with the treatment extracts to 
examine potential effects of extract dilution and exposure time on proliferation.  The 
plates were imaged using a Nikon Eclipse TE2000-U inverted fluorescence microscope 
and NIS Elements software (Nikon).   Images were analyzed with ImageJ. 
 
5.3.4 Statistical analyses 
Statistical analyses were performed to compare the results of treatment cultures 
with respect to the negative and positive controls using a one-way analysis of variance 
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with the significance of individual differences established by Tukey post-hoc test.  In all 
cases the level of statistical significance was set at p < 0.05. 
 
5.4 Results 
5.4.1 Capsule morphology 
Capsules fabricated at an agitation rate of 700 rpm were shown to have 
uniformly spherical morphology with average diameter and shell thickness of 121 ± 24 
µm and 3 ± 0.9 µm, respectively, consistent with measurements obtained previously[171, 
181].  Capsules made at this agitation rate were used for all experiments. 
 
5.4.2 Cytotoxicity testing of OCA and capsule-embedded bone 
cement 
5.4.2.1 MG63 viability 
The cytotoxic effects of leachates extracted from unfilled bone cement, bone 
cement filled with 10 wt% capsules, and OCA tissue adhesive were assessed after 72 h 
exposure using calcein AM staining to detect live cells and Hoechst 33342 staining to 
detect all cells.  Cells cultured in media containing no material extract served as negative 
controls.  Loctite® Super Glue (ethyl cyanoacrylate) and copper sheets[113] were used as 
positive controls.  Microscope images revealed that while cells in the treatment groups 
were still surviving at 72 h, the viable cells covered area less of the well when compared 
with controls that received no extract (Figures 5.2 and 5.3).  Viability was assessed as the 
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total area covered by live cells in the treatment groups compared to coverage by live 
cells observed in control samples not treated with any extract[194].   
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Figure 5.2: Viability of MG63 cells following 72 h exposure to (A) control media, (B) 
undiluted extract prepared from unfilled and (C) filled bone cements.  Green – 
calcein; blue – Hoechst 33342. 
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Figure 5.3: Viability of MG63 cells following 72 h exposure to (A) control media and 
media containing OCA extract diluted to (B) 50%, (C) 25%, and (D)10% using fresh 
medium.  Green – calcein; blue – Hoechst 33342. 
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Extracts from all bone cement specimens exhibited significantly reduced cell 
viability compared to the negative control but not with respect to each other; a slight but 
not significant dose-dependent response was also observed (Figure 5.4A).  In contrast, 
extracts from OCA-containing medium showed a significant reduction in coverage by 
live cells for all dilutions with respect to control samples and a significant dose-
dependent dilution effect was observed (Figure 5.4B).  No live cells were present 
following 72 h culture with extract from either the copper or Super Glue positive 
controls. 
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Figure 5.4: Viability of MG63 human osteosarcoma cells after 72 h exposure to (A) 
PMMA bone cement and (B) OCA extracts (average ± SEM, n=4).  Coverage by live 
cells in the positive controls, Cu and Loctite®, were significantly different from all 
treatment groups though significance is not indicated on the figures. 
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5.4.2.2 MG63 proliferation 
The effects of bone cement and OCA extracts on MG63 cell proliferation over 24, 
48, and 72 h are shown in Figures 5.5-5.8.  Compared to extract-free negative controls, 
cell proliferation was significantly reduced upon exposure to undiluted extracts from 
unfilled and filled bone cement and to 50% diluted extracts from OCA at all time points, 
but proliferation trended upwards with increased dilution of the extracts. 
Overall, microscope images revealed that cell proliferation in undiluted extracts 
from unfilled and capsule filled bone cements were nearly indistinguishable (Figure 5.5), 
indicating that the addition of capsules to the bone cement did not significantly affect 
proliferation of cells at 24, 48, or 72 h (Figures 5.8A-C).  However, the dose-dependent 
dilution effect for capsule-filled bone cement was significant only at 48 h between 
undiluted extracts and extract diluted to 25%.  
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Figure 5.5: Proliferation of MG63 cells after 24 h exposure to (A) control media and 
undiluted extracts prepared from (B) unfilled and (C) filled bone cements.  Green – 
EdU; blue – Hoechst 33342. 
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In contrast, extract obtained from OCA had a more substantial effect on 
curtailing cell proliferation, thus requiring that 50% dilution be the least diluted extract 
tested (Figure 5.6).   
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Figure 5.6: Proliferation of MG63 cells following 24 h exposure to (A) control media 
and media containing OCA extract diluted to (B) 50%, (C) 25%, and (D) 10% using 
fresh medium.  Green – EdU; blue – Hoechst 33342. 
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A significant decrease in the proliferation of cells exposed to OCA extract-
containing medium diluted to 50% was observed at each time point with respect to the 
negative control, with the largest decrease observed after 48 h (Figure 5.7).   
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Figure 5.7: Proliferation of MG63 cells exposed to OCA extract media diluted to 50% 
for (A) 24 h, (B) 48 h, and (C) 72 h.  Note the recovery of proliferation between 48 and 
72 h, suggesting the effects of OCA on MG63 cell proliferation may be transient.  
Green – EdU; blue – Hoechst 33342. 
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The dose-dependent dilution effect for OCA extract was significant between all 
dilutions at 48 h and between 50% and 10% at 72 h (Figures 5.8D-F).  Treatment with 
extract from Super Glue and copper sheets eliminated proliferation at every time point.  
Additionally, cells in all groups exhibited decreased proliferation over time. 
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Figure 5.8: Proliferation of MG63 human osteosarcoma cells in response to growth in 
extract from (A,B,C) bone cement and (D,E,F) OCA after (A,D) 24 h, (B,E) 48 h, and 
(C,F) 72 h (average ± SEM, n=4).  Proliferation of cells in the positive controls, Cu and 
Loctite®, were significantly different from all treatment groups though significance is 
not indicated on the figures. 
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5.5 Discussion 
This work is an assessment of basic biocompatibility measures for the first bone 
cement based on a self-healing material.  Each test was designed to examine how 
capsule incorporation affected the cytotoxicity of the bone cement relative to the unfilled 
control as well as how cells responded to the healing agent alone.  
Numerous investigations of the cytotoxicity of various bone cement formulations 
have been reported[113, 114, 117, 195-197].  As the toxicity associated with bone cement has been 
primarily attributed to the MMA monomer and its activator[113-115], both of which are 
unchanged in the capsule-embedded formulation, the similar cellular responses 
observed between the filled and unfilled bone cements were anticipated (Figures 5.2, 
5.4A, 5.5, and 5.8A-C).     
Similar to the results presented here, previous studies found the proliferation of 
MG63 cells to be reduced as the exposure time to bone cement extracts was increased[114].  
However, these results also indicate the addition of capsules did not significantly affect 
cell proliferation or viability in response to PMMA bone cement.  It is also accepted that 
the toxic effects of bone cement on cells and tissue primarily occurs before and during 
polymerization in vivo[114, 198]; potential evaporation of residual MMA during the curing 
and autoclaving procedures may have reduced its presence in the bone cement extracts.  
As MMA is a major toxicity concern associated with bone cement[113-115] the added 
opportunities for its removal influenced the in vitro survival and continued proliferation 
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of cells.  These in vitro analyses do not fully reflect what happens to the cells as the 
PMMA cures in vivo but do support the potential promise of the system.   
There are also numerous studies dedicated to analyses of toxicity of 
cyanoacrylate adhesives for clinical applications[191, 192, 199, 200], albeit not in the context of a 
self-healing material.  Cyanoacrylate adhesives degrade into formaldehyde and 
cyanoacetate, which may cause tissue irritation[192, 199-203].  Shorter chain cyanoacrylate 
adhesives such as the Loctite® positive control used here are known to be more toxic 
than longer alkyl chain adhesives such as OCA[192, 199-204].   
Proliferation and viability testing of OCA extracts (Figures 5.3, 5.4B, 5.6, 5.7 and 
5.7D-F) clearly showed the OCA had a toxic effect on the MG63 cells in culture, and 
extracts from the Loctite® positive control killed virtually all of the cells.  Similar to the 
work of others with various cyanoacrylates, these results showed both time- and dose-
dependent effects on cell proliferation and viability[192, 200].  While OCA extract diluted to 
50% and 25% significantly decreased proliferation with respect to the negative control, 
there was no significant decrease in proliferation of cells treated with 10% OCA extract, 
suggesting the effects of the extract were mediated through the dilution of the extract.  
Therefore, it is hypothesized that some effects of both PMMA and OCA on surrounding 
cells may be mediated through clearance (e.g. dilution) of the released leachates in vivo.  
Furthermore, as the OCA is intended polymerize within the PMMA matrix upon contact 
with moisture, limited exposure to cells is anticipated.   
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Although cell death was visualized with viability staining, in areas where the 
cells grew in large aggregates it was difficult to identify single cells to get an accurate 
measure of cell number and determine which cell nuclei were associated with each 
cytoplasmic calcein stain indicating a live cell.  Therefore, viability was determined as 
the total area covered by live cells in the treatment groups compared to coverage by live 
cells observed in control samples[194].  Quantifying viability as a measure of cell coverage 
allowed for slight changes in cell morphology to be taken into account (Figure 5.3B), but 
depends on the effects of extract on cell proliferation.  As some cells were still living 
after treatment with various extracts but their number and area coverage was 
diminished, the inhibition of proliferation may be a more sensitive marker for 
biocompatibility than viability stains; reduced proliferation could account for the 
significantly reduced coverage by live cells observed in more concentrated extracts[194].   
 
5.6 Conclusions 
The effects of extract from a capsule-embedded bone cement on the proliferation 
and viability of MG63 human osteosarcoma cells indicated the addition of capsules did 
not significantly affect the viability and proliferation of the cells in response to the 
PMMA.  The effects of both capsule-embedded bone cement and OCA extracts were 
found to be mediated somewhat through dilution of the extract.  Even though an 
extensive and comprehensive cytotoxicity analysis was not the goal of these 
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experiments, these findings support the future promise of this system and indicate its 
toxicity is similar to existing commercial formulations. 
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6. Chapter 6: Dissertation summary and future work 
6.1 Dissertation summary 
This project was motivated by the clinical need to improve the functional lifetime 
of cemented TJRs.  The following hypotheses were tested: (1) reactive OCA can be 
successfully encapsulated and the resulting capsules thoroughly characterized; (2) the 
static mechanical properties of the PMMA composite can be improved or maintained 
through inclusion of an optimal wt% of OCA-containing capsules; (3) PMMA containing 
encapsulated OCA has a prolonged lifetime when compared with a capsule-free PMMA 
control as measured by the number of cycles to failure; and (4) the addition of capsules 
to the PMMA does not significantly alter the biocompatibility of the material.   The 
specific aims of the project were to: (1) use interfacial polymerization techniques to 
encapsulate reactive OCA healing agent and characterize the properties of the resulting 
capsules; (2) determine the effects of capsule content on the tensile, compressive, and 
fracture toughness properties of PMMA to identify an optimal maximum allowable 
wt%; (3) examine the fatigue lifetime of capsule-embedded and capsule-free commercial 
samples to assess the functionality of the self-healing system; and (4) investigate the 
viability and proliferation of MG63 human osteosarcoma cells when treated with 
extracts from capsule-containing bone cement as a preliminary assessment of 
biocompatibility. 
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In Chapter 2, the optimization of the encapsulation of OCA within PUR capsules 
and subsequent capsule characterization was presented.  Interfacial polymerization of 
PUR and 1,4-BD in an oil-in-water emulsion was used to encapsulate OCA.  Average 
capsule diameter and shell thickness were dictated by agitation rate though the ratio of 
thickness/diameter remained fairly consistent, ranging from 0.01-0.02 regardless of the 
rate used during capsule fabrication.  TGA analyses revealed the multiphasic thermal 
degradation behavior of OCA-containing capsules; from this data, it was determined 
that the OCA content of the capsules ranged from 46-58% depending on the agitation 
rate used.  The compressive strength of individual capsules made at different speeds 
ranged from 8.3 to 13.6 MPa; this variability was attributed to variations in percent fill of 
the capsules as well as the shell thickness in capsules fabricated a different agitation 
rates, with thicker shells observed at slower agitation rates.  To investigate the 
functionality of the encapsulated OCA, capsules were crushed between two plates and 
the detachment force necessary to separate the bonded plates was recorded.  Finally, 
capsules were incorporated into a PMMA matrix as a preliminary assessment of process 
survivability.  Results from Chapter 2 supported the hypothesis that reactive OCA could 
be encapsulated and the resulting capsules thoroughly characterized; the results also 
supported progression to mechanical testing of capsule-embedded specimens. 
Various mechanical properties of PMMA specimens embedded with 
encapsulated OCA were determined and presented in Chapter 3.  The tensile and 
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compressive properties of the PMMA/capsule composite were maintained at capsule 
contents up to 5 wt%; above this content, the required strengths were no longer 
sustained.  Compression samples containing 10 wt% or fewer capsules deformed 
plastically upon failure whereas specimens with higher capsule contents (≥ 25 wt%) 
fragmented upon failure.   Fracture toughness was increased slightly by the inclusion of 
3 wt% capsules and remained within the range of literature-reported values for fracture 
toughness of PMMA at all capsule contents tested (0-15 wt%).  Increased fracture 
toughness suggests the ability of capsules to slow crack propagation rates to contribute 
to material lifetime extension.  The results in Chapter 3 confirmed the hypothesis that 
the static mechanical properties of a PMMA composite could be maintained or 
improved through the inclusion of an optimal wt% of OCA-containing capsules, in this 
case, up to 5 wt%. 
In Chapter 4, studies investigating the functional lifetime of capsules, the 
bending strength of capsule-containing specimens, and the effects of capsules on PMMA 
fatigue lifetime were presented.  Capsules demonstrated some susceptibility to moisture 
intrusion as evidenced by the increase in shell thickness and subsequently in individual 
capsule compressive strength.  Similar to UTS and UCS, bending strength was decreased 
with increased capsule wt% while the bending modulus remained largely unchanged 
regardless of the capsule content.  Following storage in Ringer’s solution at 37 ºC, the 
bending strengths of unfilled specimens was virtually unchanged while B of samples 
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filled with 5 wt% encapsulated OCA was increased by 17%.  The bending moduli of 
unfilled and filled specimens were reduced slightly following storage in Ringer’s; E 
decreased by 7.9% and 12.6%, respectively for unfilled and filled samples.  This decrease 
is attributed to reduced deflection undergone by samples prior to failure post-storage in 
Ringer’s solution. 
Fatigue lifetime was increased in samples containing capsules when compared 
with unfilled controls; the effect of the OCA was confirmed through cyclic testing of 
PMMA specimens containing OCA-free capsules.  At low applied cyclic loads, the index 
of fatigue performance of OCA-containing bone cement stored in air at RT was 
increased 2.5 and 1.8 times when compared to specimens containing OCA-free capsules 
and specimens without capsules, respectively.  However, when samples were tested 
following storage in Ringer’s solution, there was a pronounced effect on the fatigue 
lifetime of samples filled with encapsulated OCA while the number of cycles to failure 
of unfilled samples stored in Ringer’s was increased.  It was also determined that at 
cyclic loading to an upper force of ≤ 40 N without storage in Ringer’s solution, the OCA-
containing samples could undergo an increased number of cycles to failure with respect 
to the other specimen types.  The results of the experiments performed in Chapter 4 
support the hypothesis that PMMA containing encapsulated OCA has a prolonged 
functional lifetime as measured by the cycles to failure but that the capsules may be 
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susceptible to moisture infiltration, and therefore have a diminished functional lifetime, 
in their intended in vivo environment. 
Biocompatibility analyses of the components of the self-healing system were 
presented in Chapter 5.  Extracts from all bone cement samples were found to 
significantly reduce the viability of MG63 human osteosarcoma cells when compared to 
the negative control but not with respect to each other; additionally, a slight but not 
significant dose-dependent response was observed through extract dilution.  In contrast, 
extracts from OCA alone showed a significant reduction in coverage by live cells for all 
dilutions with respect to control samples as well as a significant dose-dependent 
dilution effect.  Compared to extract-free controls, cell proliferation was significantly 
reduced upon exposure to undiluted extracts from capsule-free and capsule containing 
controls; however, overall MG63 proliferation in undiluted extracts from capsule free 
and capsule embedded bone cements were nearly indistinguishable.  This indicates that 
the addition of capsules did not significantly affect proliferation after 24, 48, or 72 h.  A 
dose-dependent dilution effect for capsule-containing specimens was significant only at 
48 h between undiluted extract and extract diluted to 25%.   
OCA was observed to have a more substantial effect on curtailing proliferation, 
thus requiring that a 50% dilution to be the least diluted extract tested; widespread cell 
death was observed in studies performed with undiluted OCA extract.  Proliferation 
was significantly decreased in cells exposed to OCA extract diluted to 50% with respect 
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to the negative control at every time point and the largest decrease was observed after 48 
h.  Modest recovery after 72 h suggests that proliferation may not be permanently 
reduced by this extract.  There was also a significant dose-dependent effect for OCA 
extract for all dilutions at 48 h and between 50% and 10% at 72 h.  The results in Chapter 
5 confirmed that the addition of capsules to the PMMA did not significantly alter the 
proliferation and viability of cells exposed to the bone cement.  While OCA displayed 
some cytotoxic effects, they were decreased through extract dilution, suggesting that 
clearance in vivo may mediate any cell toxicity.   
Overall the results presented in this dissertation support the feasibility of a self-
healing bone cement system based on OCA.  Specifically, we found that functional OCA 
could be encapsulated within PUR shells and successfully incorporated into PMMA 
bone cement.  Lower wt% of capsules was found to maintain the tensile, compressive, 
fracture toughness, and bending properties of the PMMA.  The inclusion of 5 wt% of 
OCA-containing capsules in the matrix increased the number of cycles to failure when 
compared to unfilled specimens and those filled with OCA-free capsules while 
maintaining material biocompatibility.  It was also determined that OCA-containing 
samples had superior fatigue performance at lower loads more relevant to those 
observed in vivo.  Storage of capsules in Ringer’s solution 37 ºC resulted in increased 
individual microcapsule compressive strength; Ringer’s solution moderately affected the 
bending strength and modulus, and increased the number of cycles to failure in unfilled 
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specimens.  In OCA-filled samples, the number of cycles to failure was decreased 
following storage in Ringer’s solution for 4 weeks, suggesting capsules are susceptible to 
moisture infiltration and subsequent OCA polymerization. 
 
6.2 Future work to complete current studies 
In Chapter 3, the fracture toughness of TDCB samples of capsule-free and 
capsule-embedded PMMA was determined and presented in Figure 3.4.  In the work 
presented in Chapter 4, samples of PMMA containing OCA-free capsules were used to 
assess the effects of the capsules themselves on the fatigue properties of the material.  
The fracture toughness of samples of PMMA containing OCA-free capsules could also 
be determined to complete this study. 
Similarly, moisture infiltration into OCA-free capsules could also be investigated 
to help investigate the effects of Ringer’s on the encapsulated OCA and on the PUR shell 
itself.  The increase in capsule compressive strength observed in Figure 4.1 was 
attributed to polymerization of the core OCA contents and swelling of the PUR shell 
itself; similar analyses with OCA-free capsules could provide information that would 
support or negate the hypothesis that the PUR swelling in the Ringer’s solution over 
time contributed to increased shell thickness.  Additionally, fatigue testing of PMMA 
samples filled with OCA-free capsules following storage in Ringer’s solution at 37 ºC for 
4 weeks is also in progress.  
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To gain a better understanding of the mechanisms of OCA release in response to 
fatigue damage, dye visualization studies could aid in determining capsule distribution 
and healing agent release in response to damage.  Given the lower wt% of capsules used 
in these experiments and the opacity of the PMMA, dyes with high contrast in the green 
Palacos R material, such as Oil Red, Sudan Black B, and D&C Violet, are all currently 
under investigation for this application (work not shown).  It is hypothesized that the 
inclusion of dye would not alter the mechanical or release properties of the capsules, but 
visualization of the released contents would enable assessments of the effectiveness of 
the system.  Information on capsule distribution as well as quantification of healing 
agent release would provide valuable insights into the limits of the system. 
 
6.3 Implications of this research 
This work represents the first introduction of a matrix repolymerization-based 
SHM to a biomedical application.  As discussed in Chapter 1, over 1 million TJR 
procedures are estimated to be performed in 2013, with the numbers projected to 
increase significantly as the population ages and patients require TJRs at younger and 
more active ages.  All primary and revision procedures have the potential to fail as a 
result of accumulated material microdamage; any action taken to extend the functional 
lifetime of cemented implants could translate to years of improved patient quality of life, 
as well as reduced hospital costs.  
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The promising fatigue lifetime results presented in Chapter 4 support the 
progression of testing into more biomimetic in vitro analyses and to assessments of in 
vivo biocompatibility and functionality.  The presence of encapsulated OCA increased 
PMMA fatigue life more than the addition of capsules alone (Figures 4.4, 4.5, and 4.8), 
suggesting that encapsulation of various liquids and oils, even those not meant to react 
upon release, could be used to increase the fatigue life of other composites used across 
numerous engineering applications.  
In the most straightforward sense, this project demonstrates the encapsulation of 
cyanoacrylate that retains its functionality post-encapsulation.  This technique, or 
modified versions of it, could have applications across many engineering disciplines, 
particularly those in which toxicity of the system is less important than the water 
reactivity of the encapsulated agent.  The removal of this constraint could allow for more 
effective encapsulation procedures through the use of more toxic, though less water 
miscible, solvents and shell materials.  
The potential benefits from and enormous growth in the area of self-healing 
biomaterials are evident.  Although bone cement was selected as the focus of this 
dissertation, numerous other implants fail following years of cyclic usage and new 
designs for such implants should also be considered for additional self-healing 
applications.  These implants include artificial heart valves, load-bearing surfaces of 
TJRs, dental implants, orthopedic nails and screws, and vertebral disc replacements, 
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among others[47].  By being the first to enter this nascent field, we hope to encourage 
other biomedical engineers to utilize SHM strategies for existing applications and to 
inspire current self-healing researchers to identify uses for their techniques within 
biomaterials.   
 
6.4 Future directions for the self-healing bone cement project  
This project was intended to investigate the feasibility of a SHM based on OCA 
and PMMA bone cement.  While the results within this dissertation are promising, at 
this stage, there are numerous directions in which the project could go to develop a bone 
cement that could be clinically-implemented to reduce the likelihood of TJR failure and 
the need for revision procedures.  Future work should focus on improving the 
functional lifetime of the encapsulated material and gaining a more comprehensive 
understanding of the mechanisms of OCA release and repair within the PMMA.  More 
complex fatigue testing strategies will need to be investigated in addition to in-depth 
and clinically-relevant assessments of the material’s in vitro and in vivo biocompatibility.  
The results in Chapter 3 indicate that bonding at the capsule/matrix interface 
could be improved; capsule pull-out and crack propagation around (rather than 
through) capsules were observed in some specimens.  As presented in Chapter 4, the 
capsules also demonstrated susceptibility to moisture intrusion, thus limiting their 
storage and functional lifetimes.  Capsule mechanical strength increased following 
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exposure to physiological conditions and was attributed to polymerization of the core 
OCA material and swelling of the PUR shell material, each of which is undesirable for 
long-term stability and functionality of this self-healing system.  Potential solutions to 
these problems may require the selection of a new capsule material or modification of 
the current PUR material to increase adhesion between the capsule shell and PMMA 
matrix and to increase capsule hydrophobicity to minimize water infiltration. 
Preliminary studies were performed to functionalize the PUR shell to improve 
capsule adhesion to the matrix and increase capsule hydrophobicity.  An alkene bond 
was introduced into the small diol used as the chain extender during capsule fabrication 
(Figure 6.1).   
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Figure 6.1: The structure of the 1,4-BD chain extender currently used in encapsulation 
procedures is shown in (A) while the structure of a proposed potential chain extender, 
2-allyl-1,3-propanediol, is shown in (B). 
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Alkene bonds can be used to react with any number of chemistries to tailor the 
surface properties of the capsules but is not anticipated to react with the OCA monomer 
during encapsulation or over long storage periods.  The modified diol, 2-allyl-1,3-
propanediol (PD), has been successfully utilized in the encapsulation procedure.  As a 
proof-of-concept study to determine whether or not this modified diol could be used to 
increase PUR hydrophobicity, thin films were made by reacting the pPUR with a chain 
extender of either 1,4-BD or PD during a spin-coating process.  The films were covered 
in a 1:1 solution of 1H,1H,2H,2H-perfluorodecanethiol:isopropyl alcohol and exposed to 
UV (254 nm) light for 60 min; this particular thiol was selected because its high 
hydrophobicity allowed for easy detection via contact angle measurements.  Following 
the thiol reaction, the films were rinsed with isopropyl alcohol and F-toluene.  A 
goniometer was used to measure contact angle of films made with various combinations 
of the chain extenders treated with the thiol (Table 6.1). 
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Table 6.1: Effect of thiol functionalization on contact angle of PUR films 
Sample type Functionalization Contact angle 
PUR + 1,4-BD None 77.3 ± 0.3 
PUR + PD None 76.4 ± 1.3  
PUR + 1,4-BD Perfluorodecanethiol 78.1 ± 0.6 
PUR + PD Perfluorodecanethiol 96.7 ± 2.2 
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This data suggests that fabricating films with different the chain extenders did 
not significantly affect the PUR hydrophobicity, as indicated by the contact angles of 
77.3 ± 0.3 and 76.4 ± 1.3.  Furthermore, the thiol was observed only to react with the 
alkene present on films made with PD while the contact angle was relatively unchanged 
in films made with 1,4-BD treated with the thiol from the untreated controls.   
While a promising future direction for this project, infinitely many factors could 
be changed to tailor the properties of the PUR + PD, including: the concentration of the 
thiol solution, the type of thiol used, the UV exposure time, the solvents used for rinsing, 
etc.  Additionally, the PUR used in these experiments was fabricated using 1,4-BD as the 
soft segment; varying the ratio of 1,4-BD to PD in the pPUR itself could also play a role 
in the functionalization of the PUR material.  Other thiols, such as 6-mercapto-1-hexanol 
and (3-mercaptopropyl)trimethoxysilane could be investigated for their hydrophobicity 
and potential interactions with the PMMA matrix.  However, there are significant 
challenges to this approach, most notably, the ability to evenly functionalize the 
rounded surfaces of capsules.   
In addition to chemical modifications of the PUR already used for the OCA 
encapsulation, alterations to the physical properties of the capsule, such as changing the 
shell material[168] or adding a coating[167, 179], could be investigated to further promote 
adhesion via increased surface roughness.  Polyethylene and silica could be investigated 
as potential capsule materials given that MMA does not affect these materials and 
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therefore the capsules could be exposed to the monomer for a longer period of time, 
improving the mixability and workability of the capsule-containing PMMA.  This would 
simplify the sample preparation procedure and reduce the potential for voids and 
defects in the final capsule-embedded samples.  It may also be worthwhile to investigate 
other solvents to improve encapsulation.  In Chapter 2, data was presented indicating 
that solvent comprised less than 7% solvent[171]; given the small volume of solvent that 
remains in the final capsules, perhaps the use of a more toxic solvent would improve 
encapsulation efficiency without increasing the overall material toxicity.  Use of such 
solvents could expand the number of materials able to be used for the encapsulation 
procedure.  Previous work has also indicated the potential of encapsulations based on 
oil-in-oil-in water emulsions utilizing paraffin oil for the encapsulation of OCA[205]; this 
work could be continued in the future to determine the system’s efficacy once 
embedded into a PMMA matrix. 
Any strategies to improve shell/matrix adhesion may allow for incorporation of 
more capsules while sustaining the commercially-required static mechanical properties.  
Greater increases in fracture toughness could also be achieved from these modifications.  
Because the healing capabilities of these systems are limited by the supply of healing 
agent, the incorporation of more capsules would serve to further increase the functional 
lifetime of the SHM.  Improvement to the capsule/matrix adhesion is crucial to 
improving the static mechanical properties and perhaps to obtaining more efficient 
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healing.  Additionally, if interfacial bonding is improved, it may be possible to optimize 
the size and wt% of capsules used in the matrix to maximize the volume of available 
healing agent. 
The fatigue studies described in Chapter 4 are promising and indicate that the 
presence of OCA, not merely the addition of capsules, is contributing to lifetime 
extension, particularly at clinically-relevant loads.  If adhesion between the capsule and 
matrix could be improved, the effects may become even more pronounced.  The results 
presented here support the extension of fatigue testing to more complex models that 
mimic the loading of TJRs in vivo.  Variable amplitude loading strategies have 
previously been used to mimic the loads experienced by joints during normal activity, 
such as walking, standing, sitting, and climbing stairs[206]; such strategies could also be 
investigated for this project to more accurately reflect both the loading in vivo as well as 
the periods of rest that might be conducive to matrix repair.  Interfacial wear has been 
shown to be responsible for considerable generation of PMMA wear debris[6, 38, 135, 137, 207]; 
therefore, testing that specifically examines the ability of this SHM to repair fatigue 
damage generated from bonding defects at the cement/stem and cement/bone interfaces 
would provide valuable information about clinically-relevant failure modes.  
Additionally, testing of samples soaked in Ringer’s solution for 4 weeks indicated that 
fatigue life was increased in unfilled specimens and decreased in samples containing 
encapsulated OCA; future work should investigate strategies to protect the capsule core 
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contents.  Other work could focus on expanding the testing to be performed while 
samples are immersed in Ringer’s solution at 37 ºC, as this would also influence the 
fatigue properties and would more accurately reflect the behavior of the material in vivo. 
Although an encouraging initial study, the biocompatibility analyses presented 
in Chapter 5 should be expanded in order to make definitive claims about the suitability 
of this self-healing composite in vivo.  Given the toxicity observed with OCA extract, 
future studies should focus on growth of cells in extract medium obtained from fatigued 
samples in which encapsulated OCA has presumably been released into the PMMA to 
reflect the material’s composition in vivo; cells should also be grown in direct contact 
with the materials.  Use of primary cells, like human osteoblasts and osteoclasts, would 
provide more relevant in vitro information than that obtained from the immortalized 
MG63 human osteosarcoma line[129, 208, 209].  Furthermore, in vitro analyses of cells grown 
in direct contact with the material rather than with its extract could better indicate the 
responses to be expected in vivo.  Given the osteolysis associated with wear debris and 
subsequent TJR failure, experiments designed to quantify wear debris generation from 
unfilled and filled specimens could determine if the self-healing approach actually 
noticeably reduces material loss by minimizing crack propagation.  Investigations of 
macrophage response, particularly the production of key cytokines (TNF-alpha, IL-1, 
and IL-6) associated with osteolysis[37, 56, 210], to wear debris generated from capsule-
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embedded bone cement would provide valuable information about the potential for 
reducing osteolysis in vivo.   
Finally, an animal model is necessary to look at in vivo responses in terms of the 
biocompatibility of the material as well as its functionality[56, 141-144].  It is possible that cell 
response could be different if the material were undergoing in situ loading; for example, 
OCA release and subsequent polymerization may have different effects on cells than 
those resulting just from contact with the static material or extracts from the static 
material.  Results presented in Chapter 5 suggest that exposure to OCA released during 
material loading may result in cell death[181], although the OCA should polymerize 
inside the PMMA matrix, minimizing direct contact with cells and the interstitial fluid.  
Even though PMMA toxicity in humans is well-documented, an appropriate (i.e. load-
bearing) animal model should be identified to examine the material’s functionality and 
subsequent cytotoxicity in vivo.   
I believe that the work presented in this dissertation is promising and supports 
the feasibility of developing a self-healing PMMA bone cement/OCA SHM that could 
significantly extend the functional lifetime of TJRs and minimize the number of revision 
procedures that are required.  There are still many exciting avenues to pursue that could 
yield even more information about this material design and potentially lead to an 
improved and more robust system. 
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Appendix A: Glossary of Terms 
Abbreviation Term 
1,4-BD 1,4-butanediol 
ASTM American Society for Testing and Materials 
B Bending strength 
b Weibull slope 
BrdU 5-bromo-2’-deoxyuridine  
DBTL Di-n-butyltin dilaurate 
DCPD Dicyclopentadiene 
DEK Diethyl ketone 
DETA Diethylenetriamine 
E Bending modulus 
EdU 5-ethynyl-2’-deoxyuridine 
Epon 682 Diglycidyl ether of bisphenol-F 
Epon 828 Diglycidyl ether of bisphenol-A 
FITC Fluorescein isothiocyanate 
HOPDMS Hydoxyl end-functionalized polydimethylsiloxane 
ISO International Organization for Standardization 
K Fracture toughness 
KH-816 Cycloalipathic amine 
MEK Methyl ethyl ketone 
MIBK Methyl isobutyl ketone 
MMA Methyl methacrylate 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
MTT 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide 
ƞ Healing efficiency 
N0 Guaranteed/minimum fatigue life 
Na Characteristic fatigue life 
Nf Number of cycles to failure 
NWM Weibull mean 
OA Osteoarthritis 
OCA 2-octyl cyanoacrylate 
Pc Critical fracture load 
PD 2-allyl-1,3-propanediol 
PDES Polydiethoxysilane 
PMMA Poly(methyl methacrylate) 
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Abbreviation Term 
PI Propidium iodide 
PTSA Para-toluenesulfonic acid 
PUR Polyurethane 
RANK/RANKL Receptor activator of nuclear factor - ĸB/ligand 
RT Room temperature 
pPUR Polyurethane prepolymer 
SHM Self-healing material 
TDCB Tapered double-cantilever beam 
TDI Toluene-2,4-diisocyanate 
TJR Total joint replacement 
TNF Tumor necrosis factor 
UCS Ultimate compressive strength 
UF Urea formaldehyde 
UHMWPE Ultra high molecular weight polyethylene 
UTS Ultimate tensile strength 
WTDCB Width tapered double-cantilever beam 
YD-115 Butyl diglycidyl ether of bisphenol-A 
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Appendix B 
Permission to reuse portions of “Self-healing biomaterials” included in Chapter 1. 
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Permission to reuse “Microencapsulation of 2-octylcyanoacrylate tissue adhesive for 
self-healing acrylic bone cement” for the contents of Chapter 2. 
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